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71 Abstract
Cervical cancer develops through precursor lesions, i.e. cervical intraepi-
thelial neoplasms (CIN). These can be detected and treated before pro-
gression to invasive cancer. The major risk factor for developing cervical 
cancer or CIN is persistent or recurrent infection with high-risk human 
papilloma virus (hrHPV). Other associated risk factors include low socio-
economic status, smoking, sexually transmitted infections, and high num-
ber of sexual partners, and these risk factors can predispose to some other 
cancers, excess mortality, and reproductive health complications as well.
The aim was to study long-term cancer incidence, mortality, and re-
productive health outcomes among women treated for CIN. Based on the 
results, we could evaluate the efficacy and safety of CIN treatment prac-
tices and estimate the role of the risk factors of CIN patients for cancer 
incidence, mortality, and reproductive health.
We collected a cohort of 7 599 women treated for CIN at Helsinki Uni-
versity Central Hospital from 1974 to 2001. Information about their can-
cer incidence, cause of death, birth of children and other reproductive 
endpoints, and socio-economic status were gathered through register-
linkages to the Finnish Cancer Registry, Finnish Population Registry, and 
Statistics Finland. Depending on the endpoints in question, the women 
treated were compared to the general population, to themselves, or to an 
age- and municipality-matched reference cohort.
8Cervical cancer incidence was increased after treatment of CIN for at 
least 20 years, regardless of the grade of histology at treatment. Compared 
to all of the colposcopically guided methods, cold knife conization (CKC) 
was the least effective method of treatment in terms of later CIN 3 or cer-
vical cancer incidence. In addition to cervical cancer, incidence of other 
HPV-related anogenital cancers was increased among those treated, as 
was the incidence of lung cancer and other smoking-related cancers. 
Mortality from cervical cancer among the women treated was not sta-
tistically significantly elevated, and after adjustment for socio-economic 
status, the hazard ratio (HR) was 1.0. In fact, the excess mortality among 
those treated was mainly due to increased mortality from other cancers, 
especially from lung cancer.
In terms of post-treatment fertility, the CIN treatments seem to be safe: 
The women had more deliveries, and their incidence of pregnancy was 
similar before and after treatment. Incidence of extra-uterine pregnan-
cies and induced abortions was elevated among the treated both before 
and after treatment. Thus this elevation did not occur because they were 
treated — rather to a great extent was due to the other known risk factors 
these women had in excess, i.e. sexually transmitted infections. 
The purpose of any cancer preventive activity is to reduce cancer in-
cidence and mortality. In Finland, cervical cancer is a rare disease and 
death from it even rarer, mostly due to the effective screening program. 
Despite this, the women treated are at increased risk for cancer; not just 
for cervical cancer. They must be followed up carefully and for a long pe-
riod of time; general health education, especially cessation of smoking, 
is crucial in the management process, as well as interventions towards 
proper use of birth control such as condoms.
92 Finnish summary
Kohdunkaulan syöpä kehittyy todettavien ja hoidettavien esiasteiden 
kautta. Tunnetuin ja tärkein riskitekijä sekä kohdunkaulan syövän, että 
kohdunkaulan syövän esiasteiden kehittymiselle on suuren riskin ihmi-
sen papilloomavirusinfektio (hrHPV). Muita merkittäviä riskitekijöitä 
ovat mm. sukupuoliteitse välittyvät taudit sekä tupakointi, jotka ovat riski-
tekijöitä myös tietyille muille syöville, lisääntyneelle kuolleisuudelle sekä 
lisääntymisterveyteen liittyville komplikaatioille.
Väitöskirjatutkimuksen tavoitteena oli selvittää pitkän aikavälin syö-
päilmaantuvuutta, -kuolleisuutta sekä lisääntymisterveystapahtumia 
kohdunkaulan syövän esiasteesta hoidetuilla naisilla. Tulosten perusteel-
la oli tarkoitus arvioida esiastehoitojen vaikuttavuutta ja turvallisuutta, 
sekä kartoittaa muiden tässä joukossa lisääntyneiden riskitekijöiden vai-
kutusta yleiseen sairastavuuteen ja kuolleisuuteen.
Tutkimusaineisto koostui 7599:stä HYKS Naistenklinikalla vv. 1974–
2001 kohdunkaulan syövän esiasteesta hoidetusta naisesta. Tieto myö-
hemmästä syöpäilmaantuvuudesta, kuolinsyistä, lasten syntymäpäivistä, 
muista lisääntymisterveydellisistä muuttujista, sekä sosioekonomisen 
aseman luokitus hankittiin yhdistämällä tutkimusaineisto Suomen Syö-
pärekisterin, Väestörekisterin sekä STAKESin (nyk THL) kanssa. Riippuen 
osatutkimuksesta, hoidettuja naisia vertailtiin joko muuhun väestöön, it-
seensä, tai ikä- ja asuinkuntakaltaistettuun vertailuväestöön.
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Kohdunkaulan syövän ilmaantuvuus oli koholla kahdenkymmen vuo-
den ajan hoidetun levyepiteeliperäisen esiasteen jälkeen, riippumatta 
esiasteen vaikeusasteesta. Myös muiden HPV-riippuvaisten anogenitaa-
lialueen syöpien (vagina-, vulva- ja anussyöpä), keuhkosyövän ja muiden 
tupakointiin liittyvien syöpien ilmaantuvuus oli koholla esiastehoidetuil-
la naisilla muuhun väestöön verrattuna. Eri hoitomuotojen keskinäises-
sä vertailussa CIN 3- ja kohdunkaulan syövän ilmaantuvuus oli suurinta 
veitsikonisaation jälkeen.
Hoidon jälkeisen fertiliteetin suhteen esiastehoito on turvallinen: Esi-
asteesta hoidetut naiset tulivat vertailuväestöä useammin raskaaksi, sekä 
synnyttivät useammin hoidon jälkeen verrattuna hoitoa edeltäneeseen 
ajanjaksoon. Kohdunulkoisten raskauksien ja raskaudenkeskeytysten 
ilmaantuvuus oli hoidetuilla verrokkeja suurempaa sekä ennen että jäl-
keen hoidon: Kyseinen havainto ei siis liity itse hoitoon vaan pikemmin-
kin muihin riskitekijöihin, mm. klamydiainfektioon, joita esiastepotilailla 
on keskimäärin muuta väestöä yleisemmin. 
Minkä tahansa seulontaohjelman tai muun syövänehkäisytoimin-
nan lopullisena päämääränä on ehkäistä  syöpäkuolleisuutta. Suomessa 
kohdunkaulan syöpä on nykyään harvinainen sairaus ja kuolema tähän 
syöpään on vieläkin harvinaisempaa, ennen kaikkea tehokkaan seulonta-
ohjelman ansiosta. Tästä huolimatta sekä kohdunkaulan että muutamien 
muiden syöpien riski on kohdunkaulan syövän esiasteen sairastaneilla 
lisääntynyt muuhun väestöön verrattuna. Hoidettuja naisia pitää seurata 
tarkasti ja riittävän pitkän ajan. Yleinen terveysvalistus, erityisesti kannus-
taminen tupakoinnin lopettamiseen ja kondomin käyttöön ovat tässä toi-
minnassa erityisasemassa. 
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4 Abbreviations
AIS adenocarcinoma in situ
AGC-FN atypical glandular cells, favor neoplasia
AGC-NOS atypical glandular cells not otherwise specified
ASC-H atypical squamous cells, HSIL not excluded
ASC-US atypical squamous cells of unknown significance
CI 95% confidence interval
CIGN cervical intraepithelial glandular neoplasia
CIGN 1 cervical intraepithelial glandular neoplasia, grade 1
CIGN 2 cervical intraepithelial glandular neoplasia, grade 2
CIN cervical intraepithelial neoplasia
CIN 1 cervical intraepithelial neoplasia, grade 1
CIN 2 cervical intraepithelial neoplasia, grade 2
CIN 3 cervical intraepithelial neoplasia, grade 3
CIN 3+ cervical intraepithelial neoplasia, grade 3 
 or invasive carcinoma
CIN NOS cervical intraepithelial neoplasia, grade 
 not otherwise specified
CKC cold knife conization
Cryo cryocoagulation
DNA deoxyribonucleic acid
HIV human immunodeficiency virus
HPV human papilloma virus
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HR hazard ratio
hrHPV high-risk human papilloma virus
HSIL high-grade squamous intraepithelial lesion
ICD International Classification of Diseases
IRR incidence relative risk
LEEP / LLETZ loop electrosurgical excision procedure
LSIL low-grade squamous intraepithelial lesion
NETZ needle excision of the transformation 
 zone / needle conization
OR odds ratio
pPROM premature prelabor rupture of the fetal membranes
PPV positive predictive value
RCT randomized controlled trial
SCJ squamocolumnar junction
SIR standardized incidence ratio
SMR standardized mortality ratio
STAKES national research and development centre for welfare 
 and health (nowadays THL)
TBS the Bethesda system
THL National Institute for Health and Welfare
TZ transformation zone
WHO World Health Organization
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5 Introduction
Cancer of the uterine cervix (cervical cancer) is the third most common 
cancer among women worldwide. Over 85% of new cervical cancer cases 
occur in developing countries, where it is in many regions the most com-
mon cancer among women, constituting up to 13% of all new cancer cas-
es. (Ferlay et al 2010). In Finland, an organized screening program for cer-
vical cancer was launched regionally in 1963 and became nationwide in 
the early 1970’s (Hakama and Räsänen-Virtanen 1976, Anttila et al 1999). 
Like other countries with a long history of organized screening programs 
for cervical precancerous lesions, age-adjusted cervical cancer incidence 
and mortality rates have been reduced by up to 80% in Finland since its 
introduction of the mass screening program (Hakama and Räsänen-Vir-
tanen 1976, Hakama 1982, Hristova and Hakama 1997, Anttila et al 1999).
Even though nowadays it is very clear that for development of cervi-
cal cancer the Human Papilloma Virus, HPV, is essential, it is neither the 
sole nor a sufficient cause of the disease. Other factors playing their part 
in development of the disease include low socio-economic status, mari-
tal status, early age of sexual debut, use of oral contraceptives, alterations 
in the immune system (HIV infection), high number of sexual partners, 
multiparity, Chlamydia Trachomatis infections, and tobacco smoking 
(International Agency for Research on Cancer 2005). All these factors not 
only contribute to the development of cervical cancer: They are risk fac-
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tors for other cancers (HPV, smoking) as well, they can be considered as 
determinants of health-care consumption and even life expectancy in 
general (socio-economic status, age), they can predispose to other mor-
bidity (smoking for cardiovascular diseases) and to reproductive health 
complications and fertility (smoking, genital infections). Women treated 
for CIN are not only CIN patients; They possess a cluster of risk factors 
for other medical conditions, which may later cause other morbidity, and 
influence their overall survival.
Figure 1 Uterine Cervix. Time trends in cervical cancer incidence 
and mortality in Finland and in all Nordic countries.
1955 1960 1970 1980 1990 20001965 1975 1985 1995
30
25
20
15
10
5
0
2005
ASR (Nordic) age (0–85  ), rate per 100 000+
Incidence-Nordic countries
Incidence-Finland
Mortality-Finland
Mortality-
Nordic countries
NORDCAN © Association of the Nordic Cancer Registries (29.9.2010)
16
6 Review of the literature
6.1 Cervical intraepithelial neoplasia
6.1.1 Definition
Most cervical cancers are derived from the epithelial tissue of the uterine 
cervix, meaning that they are carcinomas. The epithelium of the uterine 
cervix comprises both squamous and columnar epithelium, separated 
by a transformation zone, (TZ), where the columnar epithelium is slowly 
replaced through metaplasia during several years by stratified squamous 
epithelium. The border between these two epithelium types is called the 
squamocolumnar junction (SCJ). Most squamous-cell dysplasias develop 
within the transformation zone and most glandular carcinomas inside 
the cervical canal near the SJC. Squamous cell cervical cancer develops 
through premalignant intraepithelial lesions, dysplasias called cervical in-
traepithelial neoplasias (CIN). The only well-known precursor of cervical 
adenocarcinoma is adenocarcinoma in situ, (AIS), whose natural course 
is poorly understood (International Agency for Research on Cancer 2005). 
A histopathological diagnosis of cervical intraepithelial glandular neopla-
sia (CIGN) grades 2–3 also exists (Gloor and Hurliman 1986).
At the cellular level, a combination of disturbed cellular maturation, 
nuclear and cytoplasmic polymorphism, and increased cellularity is ob-
servable in CIN lesions. These premalignant cells already present with 
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several malignant features, such as cellular overcrowding, hyperchromatic 
nuclei, and nuclear polymorphism. These cells are intraepithelial, strictly 
restricted to the epithelium: The basement membrane is not breached, 
and no features characteristic for cancer such as infiltrative or metastatic 
growth exist (MacSween and Whaley 1992, Tavassoli and Devilee 1993).
Cervical intraepithelial neoplasias are graded in three categories: 
CIN 1, CIN 2, and CIN 3, depending on the thickness of the epithelium 
harbored by the dysplastic epithelial cells. The CIN 1 lesion is restricted to 
the lowest third of the epithelium, CIN 2 constitutes two-thirds of the epi-
thelium, and CIN 3 affects the whole depth of the epithelium (MacSween 
and Whaley 1992).
6.1.2 Etiology
Persistent or recurrent infection with high-risk human papilloma virus 
(hrHPV) types is a necessary, but not sufficient cause of CIN and cer-
vical cancer (zur Hausen 1976, Munoz et al 1992, Bosch et al 1995, Zur 
Hausen 2000). HPV DNA can be detected practically always in cancer tis-
sue (Clifford et al 2003, Munoz et al 2003). Human papillomaviruses are 
Figure 2 Epithelial changes in different levels of dysplasia or CIN.
Microinvasive Carcinoma
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Grade 1 Grade 2 Grade 3
Cervical Intraepithelial Neoplasia (CIN)
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double-stranded, non-enveloped DNA viruses that infect differentiating 
epithelial cells of the skin and mucosa (International Agency for Research 
on Cancer 2007). Over 130 different HP viruses have been identified (In-
ternational Agency for Research on Cancer 2007), and approximately 40 
types of them are capable of infecting the anogenital area (de Villiers et al 
2004). These viruses are again classified into low- and high-risk types ac-
cording to their association with various cervical lesions: The former are 
mainly involved in development of genital warts and mild dysplasia, and 
the latter in the development of malignant neoplasia. The most common 
hrHPV types, 16 and 18, are detected in approximately 70% of all cervical 
cancers worldwide (Munoz et al 2004). Other high-risk HPV types include 
33, 45, 31, 58, 52, 35, 59, 56, 51, 39, 73, 68, and 82, in their order of decreas-
ing worldwide prevalence (Clifford et al 2003, Munoz et al 2003). Their 
carcinogenic potential varies significantly, and a recent review concluded 
that HPV types 45, 31, 33, 35, 52 and 58, together with 16 and 18, are the 
most important hrHPV types globally in terms of carcinogenic potential. 
(Schiffman et al 2009)
In addition to HPV, smoking, early sexual debut, multiparity, high 
number of sexual partners, smoking, other genital infections — especially 
Chlamydia Trachomatis, human immunodeficiency virus (HIV), use of 
oral contraceptives, and low socio-economic status are known risk factors 
for CIN and squamous cell cervical cancer (Terris et al 1967, Koutsky et al 
1992, Deacon et al 2000, Anttila et al 2001, Castellsague et al 2002, Smith et 
al 2004, International Agency for Research on Cancer 2005, Castellsague 
2008). Apart from smoking, the risk factors for both squamous cell and 
columnar cell cervical carcinoma are identical (Berrington de Gonzales 
et al 2004).
The association between smoking and CIN is well documented: CIN 
patients are more likely to smoke more often than does the general popu-
lation (Vaccarella et al 2008), and the current opinion is that smoking is an 
independent risk factor for cervical intraepithelial neoplasia (Burger et al 
1993, Kjellberg et al 2000) and for squamous cell cervical cancer (Plum-
mer et al 2003, Appleby et al 2006, Kapeu et al 2009). 
Development of CIN has also been associated with the use of oral con-
traceptives. The relative risk for CIN among oral contraceptive users is in-
creased and declines after cessation of usage (Moreno et al 2002, Smith 
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et al 2003, Appleby et al 2007). It is still difficult to differentiate whether 
oral contraceptive use is directly associated with CIN development, or 
whether oral contraceptive use elevates the rate of new or recurrent HPV 
infections and therefore of CIN incidence. Supporting this theory of indi-
rect association, a study by Castle et al (2005) concluded that “Oral contra-
ceptive use, Norplant® (implantable hormonal contraceptive) use, a his-
tory of pregnancy, age at first pregnancy, lifetime numbers of pregnancies 
and lifetime numbers of live births were not associated with CIN 3, when 
CIN 3 incidence was analyzed only from women with high grade HPV” 
(Castle et al 2005).
Because CIN is caused by infection, women with HIV or other immu-
nosuppressive conditions are at increased risk for cervical cancer and its 
precursors (Birkeland et al 1995, Frisch et al 2000, International Agency 
for Research on Cancer 2005).
6.1.3 Natural history of HPV infection
Sexual transmission is the dominant route of acquiring anogenital HPV 
infection (Ley et al 1991, Bauer et al 1993, Rylander et al 1994, Fran-
co 1995, Dillner et al 1999), and usually the infection is acquired at a 
young age, within a few years of the sexual debut (Koutsky et al 1992, 
Melkert et al 1993, Ho et al 1998, Rodriguez et al 2007). Condom use 
does not protect against HPV infection (Manhart and Koutsky 2002), 
but the incident HPV infections were 70% less common among regular 
condom users than among those who used condoms in less than 5% of 
the time, HR 0.5 (95% CI 0.1–0.6) (Winler et al 2006). In a Finnish study, 
genital HPV appeared in 15% of all infants at birth, declining to 10% at 
24 months, with oral HPV in the mother as a risk factor for this (Rintala 
et al 2005). 
Most HPV infections are transient, and they clear within months. 
Median duration of HPV infection among young women aged 13 to 23 
was 8 months, and the cumulative 36-month HPV incidence of being 
HPV-negative has been 43%. Increasing age and infection with multiple 
HPV types has been associated with lower rate of HPV clearance from 
the cervix. (Ho et al 1998). Most infections are cleared by the immune 
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system within a few months, but hrHPV infections, especially HPV 
16-infections, last a couple of months longer than do infections from 
low-risk HPV types (Richardson et al 2003). In one Finnish cohort, a 
third of a population of university students had a prevalent HPV infec-
tion, and 84% of these were hrHPV infections (Auvinen et al 2005). In 
Finland, the prevalence of high-risk HPV infection among women at 
screening age (30–65 years) is about 7% (Syrjänen et al 1992, Leino-
nen et al 2009). Over 50% of all non-specific HPV-related changes in 
cytological examination (ASC-US-LSIL) regress spontaneously with-
out treatment (Melnikow et al 1998, Moscicki et al 2001, 2004). Infec-
tion with high-risk HPV persisting for over 6 months leads to an in-
creased probability of developing dysplasia (Ho et al 1998, Moscicki 
et al 2001). 
According to current knowledge, cervical cancer develops through 
precancerous lesions preceded by a persistent HPV infection (Koutsky 
et al 1992, Ho et al 1995, Remmink et al 1995, Ho et al 1998, Nobbenhuis 
et al 1999). Persistent HPV infections in the TZ of the cervix can result 
in either productive, self-limited HPV infections, or in infections with 
the potential to progress to invasive squamous cell carcinoma (Wright 
et al 2002). A typical cytological sign of productive HPV infections of 
the cervix is a low-grade squamous intraepithelial lesion (LSIL), and 
the corresponding histological lesions include condyloma and mild 
dysplasia (CIN 1). Histological lesions with the potential to progress 
to cervical cancer include moderate dysplasia (CIN 2), severe dyspla-
sia, and carcinoma in situ (CIN 3). The corresponding cytological le-
sion for these is a high-grade squamous intraepithelial lesion (HSIL) 
(Wright et al 2002). 
In transitional cervical infections, the HPV DNA remains episomal, 
but especially in CIN 3 and invasive cancer lesions the HPV DNA can 
become integrated into the host genome (Boshart et al 1984, Schwartz 
et al 1985), and this can result in genetic instability, secondary somatic 
mutations, and growth advantage in these cells with integrated HPV 
DNA (Jeon et al 1995, Zur Hausen 2000). Several studies have found 
only episomal HPV DNA in CIN 3 and cervical cancer cells (Fuchs et al 
1989, Cullen et al 1991, Pirami et al 1997). The role of the HPV genome 
integration in cells therefore remains somewhat controversial.
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6.1.4 Natural History of CIN 
All CIN lesions are dynamic. They regress, persist, and progress at differ-
ent rates over time, depending on the age of the woman, the grade of the 
lesion, persistence of the HPV infection, and on other risk factors such as 
smoking (International Agency for Research on Cancer 2005). Due to this 
and the variable endpoints used, CIN progression and regression rates 
vary significantly between studies.
Generally over 90% of all grades of CIN regress spontaneously among 
women aged under 22 (Moscicki et al 2004). This probability of spontane-
ous regression decreases with increasing age: Among women under 34, 
84% (CI 76%–92%) of the new lesions (CIN 1–3) are estimated to regress 
spontaneously, but among women over the age of 34, only 40% of the new 
lesions seem to regress spontaneously (van Oortmarssen and Habbema 
1991). Of cervical carcinoma in situ, 61% regressed spontaneously among 
women age 40 to 64, 70% among women 25 to 54, and 77% among wom-
en 15 to 39 (Boyes et al 1982). In an RCT performed in the Netherlands, 
women with an unspecified grade of CIN were assigned to regular con-
dom use for at least 3 months or to a control group. The cumulative 2-year 
Figure 3 Cervical cancer development.
Exposure
Clearance Regression
Progression
Transient infection Persistent infection
HPV
Normal CIN 1 CIN 2 CIN 3 Cancer
Normal 
cervix
Productive 
infection
Precursor
lesion
Invasive
lesion
Genetic instacility
Development of aneuploidy
LOH at various loci
22
regression rate of CIN was 53% among the condom users and 35% in the 
non-condom group (p= 0.03) (Hogewoning et al 2003).
Most low-grade lesions regress spontaneously, and progression rates 
into cancer are estimated to be very small. In a cohort of 528 women 
with LSIL or HSIL in a PAP smear, progression to CIN 2 or higher over the 
follow-up of 6 years in a Finnish cohort study was 14% among untreated 
women (Syrjänen et al 1992). The CIN 2 lesions progress more often, and 
in the same cohort the progression rates for CIN 2 and CIN 3 (with expan-
sion of the detected CIN 3 lesion interpreted as progression of CIN 3) were 
21% for CIN 2 and 69% for CIN 3 in the 6 years of follow-up (Syrjänen et 
al 1992). In this same cohort, 47% of women with initial LSIL and 38% of 
women with initial HSIL were under age 24 at the beginning of follow-up. 
The regression rate in this cohort for CIN 2 was 53% and for CIN 3, 14%. 
In a Canadian historical cohort study of the PAP smear and biopsy his-
tory of women treated for CIN, the progression rates from CIN to cancer 
for CIN 1 was 0.4% (95% CI 0.3–0.5%), for CIN 2, 1.2% (CI 0.9–1.5%), and 
for CIN 3, 3.9% (CI 2.0–5.8%) (Holowaty et al 1999). The suggested pro-
gression rates of carcinoma in situ to cervical cancer range from 28 to 39% 
based on Finnish Cancer Registry data on cervical cancer incidence in a 
screened population, (Hakama and Räsänen-Virtanen 1976), to 15 to 23% 
according to a Swedish population-based study on invasive cancer and 
cervical carcinoma in situ incidence between 1958 and 1981 (Gustafsson 
and Adami 1989), and to 36% in a literature review (Mitchell et al 1996). 
A cohort study from New Zealand, a retrospective nationwide follow-up 
with 14% of women lost to follow-up, estimated that among women with 
untreated CIN 3, 20.0% (CI 13.7–28.7%) developed invasive cervical or 
vaginal cancer within 10 years and 31.3% (CI 22.7–42.3%) within 30 years 
(McCredie et al 2008). 
Several studies have estimated the CIN grade-dependent progression 
and regression rates over the years. In one of the most prominent, a review 
by Östör (1993), the duration of follow-up and age at treatment were not 
considered in detail, and therefore the study is very likely to underestimate 
the real long-term progression rates from CIN into cancer (International 
Agency for Research on Cancer 2005, European Guidelines for Quality As-
surance in Cervical Cancer Screening 2008) and this is not therefore fur-
ther considered here.
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The progression from hrHPV infection to cervical cancer takes de-
cades. The time from HPV infection to carcinoma in situ is estimated to 
be at least 7 to 9 years (Ylitalo et al 2000b), the average duration of the 
dysplasia and carcinoma in situ stage has been estimated to be 11.8 years 
(van Oortmarssen and Habbema 1991); the duration of the carcinoma in 
situ stage alone has been suggested to be at least 5 to 10 years (Kasper et al 
1970, Prorok 1986), however. 
A model-based study using some of the progression and regression 
estimates referred to above estimated the lifetime incidence of cervical 
cancer in an unscreened population to be 3.67% with a lifetime cervical 
cancer mortality risk of 1.26%, They concluded that, based on the model, 
“ the incidence of HPV infections, the proportion of rapidly progressive 
infections, and low-grade SIL progression rates appear to have the largest 
impact on cervical cancer risk,” highlighting the possible effectiveness of 
primary prevention modalities against cervical cancer (Myers et al 2000).
6.2 Diagnosis and treatment of CIN
6.2.1 Diagnosis
In Finland about 850 women are annually diagnosed with CIN 3, and about 
150 with cervical cancer (Finnish cancer registry 2010). No nationwide reg-
ister of CIN 1 and 2 lesions exists. The incidence of CIN 3 lesions in the Finn-
ish Cancer Registry might well be an underestimation due to poor compli-
ance in notifying the detected CIN 3 lesions to the Finnish Cancer Registry. 
Early detection and treatment of HPV-related precancerous lesions, CINs, 
by nationwide screening has reduced the cervical cancer incidence and 
mortality in Finland by 80% since introduction of screening in the early 
1960’s (Läärä et al 1987, Anttila et al 1999, International Agency for Research 
on Cancer 2005). Since the 1990’s, however, the incidence of cervical cancer 
has increased in Finland, especially among the youngest screening cohorts, 
women aged 30 to 39 years (Finnish Cancer Registry). The reason for this is 
both the low attendance rate at screening among these younger women as 
well as the simultaneous increase in HPV 16 incidence and seroprevalence 
in the same age cohort (Laukkanen et al 2003, Harper et al 2010)
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The detection of cervical precancerous lesions has been based on ex-
foliative cytology, traditionally on the PAP smear, named after its inven-
tor, Georgios Papanicolaou (Papanicolaou 1928, Papanicolaou and Traut 
1941). It consists of three individually scraped samples of the vagina, 
cervix, and endocervix, all collected on the same microscope glass slide. 
The sample is then immediately fixed and stained with modified Papani-
coloau staining. Within the nationwide screening-program, the sample is 
prescreened by a cytotechnician and after that examined by a cytopathol-
ogist. The current cytological terminology recommended for use world-
wide to describe findings in the PAP smear is The Bethesda System, from 
the year 2001, (TBS 2001). It evaluates the adequacy of the specimen, gives 
a descriptive diagnosis, and distinguishes between intraepithelial atypia 
and infectious or reactive changes (Solomon et al 2001). All these features 
were missing from the original five-step Papanicolaou class report of the 
specimen (Papanicolaou 1954) (Table 1).
According to Finnish legislation, communities must organize mass 
screening for cervical cancer for women aged between 30 and 60 at 5-year 
intervals. Currently the screening is PAP smear-based, but recently HPV 
test-based screening has been suggested as the primary screening meth-
od due to its higher sensitivity in CIN detection (Leinonen et al 2009, San-
karanarayanan et al 2009, Anttila et al 2010, Ronco et al 2010).
The diagnostics of cervical epithelial cellular alterations is currently 
based mainly on cytology. Specific guidelines have been assessed, ac-
cording to which women with different cytologically detected changes are 
Table 1 TBS 2001 and CIN classifications of squamous 
cell lesions according to Papanicolaou class.
Papanicolaou I II III IV V
CIN Normal Atypia CIN 1,2 & 3 CIN 3 Invasive SCC
TBS 2001
Negative for
epithelial
abnormality
ASC-US +
LSIL
LSIL + HSIL ASC-H &
HSIL
Invasive SCC
CIN = cervical intraepithelial neoplasia; SCC = cervical squamous cell cancer; TBS 2001 = the Bethesda System 
2001; ASC-US = atypical squamous cells of unknown significance; LSIL = low-grade squamous intraepithelial 
lesion; HSIL = high-grade squamous intraepithelial lesion; ASC-H = atypical squamous cells, HSIL not excluded.
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referred for resampling or colposcopy during which histological samples 
(biopsies) are taken (Finnish Current Care guidelines 2010). The termi-
nology for describing the histological grade of the precancerous lesion is 
called the CIN terminology (Richart 1968, 1973).
6.2.2 Colposcopy
According to Current Care Guidelines in Finland, cytological indications 
for colposcopy are:
 
	 •	Macroscopic	suspicion	of	cancer	and	carcinoma	in	a	cytological	sample
	 •	AIS,	HSIL,	ASC-H,	AGC-FN,	and	atypical	columnar	endometrial	cells	
  (when diagnosis is not reached with an endometrial sample and 
  ultrasound examination)
	 •	LSIL:	for	women	over	age	30.	Women	under	30	according	to	
  recommendation of a cytopathologist or when ASC-US or a more 
  severe lesion is detected in the follow-up PAP smear taken 6 to 
  12 months after the initial PAP smear.
	 •	ASC-US	when	repetitive	2	to	3	times	within	12	to	24	months,	
  or ASC-US and hrHPV positive and aged over 35.
	 •	AGC-NOS,	when	detected	twice	within	4	to	6	months
	 •	Strong	regenerative	cytology	or	inflammation	when	repeatedly	
  discovered according to a cytopathologist’s recommendation.
The colposcope was first described by Hinselmann (1925). The basic 
principle has remained the same to date; the colposcope is a binocular 
light microscope allowing the cervix to be magnified up to 40 times its nor-
mal size (Anderson et al 1996).  The cervix is visualized with a speculum, 
and the colposcopic examination for abnormalities includes examination 
of the squamous epithelium, the TZ, the squamocolumnar junction, and 
the visible part of the columnar epithelium (Coppleson et al 1978). Dur-
ing the examination, a 3 to 5% acetic acid solution is applied to the cervix. 
This causes tissue swelling and coagulation of the superficial intracellular 
proteins that can be observed as reduced transparency and whitening of 
the epithelium (acetowhitening) (Anderson et al 1996). 
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The colposcopical examination and interpretation is based on visual pat-
terns of acetowhitening and on vascular patterns. Changes in subepithelial 
angioarchitecture suggestive for CIN are punctuation, mosaic, and atypical 
vessels. High-grade lesions are more densely aceto-white than low-grade le-
sions, and the borders of high-grade lesions have sharp edges, whereas the 
edges in low-grade lesions can be indistinct. (European Guidelines for Qual-
ity Assurance in Cervical Cancer Screening 2008). 
From the areas where the acetowhitening is most prominent — the most 
suspicious areas in terms of possible CIN — punch biopsies, more than one 
if necessary, are taken under colposcopical control. The biopsy must include 
both the surface epithelium and the stroma to indicate whether the lesion is 
intraepithelial. Usually no local anesthesia is required (Finnish Current Care 
guidelines 2010).
All acetowhite areas are not premalignant, and this phenomenon can 
be observed in immature squamous metaplasia, in healing or regenerating 
epithelium,  in HPV infection, and in invasive carcinoma as well (European 
Guidelines for Quality Assurance in Cervical Cancer Screening 2008). This 
is the reason for generally low specificity of colposcopy, 48% on average for 
diagnosing any abnormality and 69% for diagnosis of high-grade (CIN 2 & 
CIN 3) or invasive lesions, compared to sensitivity of 96% for any abnormality 
and 85% for high-grade and invasive lesions (Mitchell et al 1998). In anoth-
er study where biopsy specimens were taken not only from colposcopically 
suspect areas but also routinely from all quadrants of TZ with endocervical 
curettage, the sensitivity of CIN 2+ detection for colposcopy was 57% (95% 
CI 52–62%) (Pretorius et al 2004). A review of the literature estimated that the 
positive predictive value (PPV) for colposcopy is 78% in detecting CIN 3 le-
sions, and smaller in detecting CIN 1 and 2 lesions (Hopman et al 1998).
6.2.3. Management of CIN
Diagnosis of CIN 1 is not always reliable, and its histological reproducibil-
ity is poor (Stoler and Schiffman 2001). Moreover, CIN 1 lesions have a high 
probability of regression, especially among women under 30 (Moscicki et al 
2004). Because of this, CIN 1 lesions can be followed for spontaneous regres-
sion for up to 12 to 24 months (European Guidelines for Quality Assurance 
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in Cervical Cancer Screening 2008, Finnish Current Care guidelines 2010). 
Finnish current care guidelines recommend that women be treated for CIN 1 
after 24 months of persistence, regardless of their age (Finnish Current Care 
guidelines 2010). Historically, all CIN lesions have been treated in Finland.
CIN 2 and CIN 3 lesions are virtually always treated because of their 
higher probability of progression (European Guidelines for Quality As-
surance in Cervical Cancer Screening 2008, Finnish Current Care guide-
lines 2010). Histologically verified precursors of cervical adenocarcinoma 
AIS and cervical intraepithelial glandular neoplasias, grades 2–3 (CIGN 
2–3) are always treated. Moreover, diagnostic LLETZ is nearly always 
performed for cytologically detected high-grade glandular changes: for 
atypical glandular cells, favor neoplasia (AGC-FN) and for 24 months 
persistent low-grade glandular changes, i.e. atypical glandular cells not 
otherwise specified (AGC-NOS) (Finnish Current Care guidelines 2010). 
During pregnancy their treatment is recommended only in case of suspi-
cion of invasion (Finnish Current Care guidelines 2010)
The treatment procedure is performed under colposcopical control, 
under local anesthesia, on an outpatient basis. The cervical epithelium is 
stained with acetic acid, and the whole treatment procedure is performed 
through a colposcope. The aim of the treatment procedure is to remove or 
destroy the whole TZ and the lesion within.
Excisional procedures are nowadays preferred in most circumstances 
because of the possibility to examine the removed tissue as a histological 
specimen, providing information about the success of the procedure and 
confirming the CIN grade. Guidelines recommend that excision be man-
datory when the lesion extends into the endocervical canal, i.e. when the 
lesion is not fully visible or when a persistent or recurrent lesion is treated 
(Finnish Current Care guidelines 2010).
The complete TZ including the preinvasive lesion is excised. Excision-
al techniques have been: 
	 •	LLETZ,	excision	of	the	TZ	using	a	diathermy	loop;	
  used in Finland nowadays nearly always
	 •	CKC,	removal	of	cervical	tissue	by	means	of	a	knife
	 •	Laser	excision,	removal	of	cervical	tissue	with	a	CO2	
  laser in the cutting mode 
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	 •	Needle	excision,	NETZ,	excising	the	TZ	with	a	straight	diathermy	wire
Current guidelines in the EU and Finland reserve the use of ablative 
techniques for lesions in which the entire TZ must be visible (European 
Guidelines for Quality Assurance in Cervical Cancer Screening 2008, 
Finnish Current Care guidelines 2010). The most common destructive 
method in Finland, cryotherapy, requires a double freeze-technique 
(Schantz and Thormann 1984). In addition, the lesion must occupy no 
more than 75% of the ectocervix, the lesion must not extend into the vag-
inal wall, to the endocervix, or more than 2 mm beyond the cryoprobe. 
There should be no evidence of invasive or glandular disease prior to 
the treatment, and prior to the ablative treatment, a biopsy is taken from 
most suspicious part of the lesion, and histological grade must corre-
spond to the cytological grade of the lesion (European Guidelines for 
Quality Assurance in Cervical Cancer Screening 2008, Finnish Current 
Care guidelines 2010). When an ablative therapy is used, the TZ destruc-
tion should extend beyond the margins of the lesion and should be, at 
minimum, of a depth of 4 to 7mm.
The aim of local destructive / ablative therapy is to destroy the CIN. 
The techniques used are: 
	 •	Cryotherapy,	in	which	a	probe	is	applied	to	
  the tissue that is destroyed by freezing 
	 •	Laser	vaporization,	in	which	CO2	laser	at	high	power	
  vaporizes the water in the cell and destroys the tissue 
	 •	Radical	diathermy,	in	which	a	straight	electrodiathermy	needle	is	
  applied and destroys the tissue to an approximately depth of 1cm
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6.3 Short-term outcomes after CIN treatment
6.3.1 Treatment complications 
After local treatment of CIN, immediate complications include periopera-
tive pain and bleeding, secondary bleeding after the procedure, leucor-
rhea, infections, and cervical stenosis (Finnish Current Care guidelines 
2010). These are generally uncommon, and no clear differences exist in 
the incidence of these complications between treatment methods (Lars-
son et al 1982, Berget et al 1987, Oyesanya et al 1993, Martin-Hirsch et al 
2010). Pain is experienced by 2 to 18% of women, and disturbing bleeding 
occurs among 2 to 12% (Martin-Hirsch et al 2010).
6.3.2 CIN persistence and recurrence 
Success rates, i.e. absence of recurrent or residual disease within a few 
years after LLETZ, CKC, laser conization, or laser ablation, range from 90 
to 98% (Larsson 1983, Jordan et al 1985, Bostofte et al 1986, Tabor and Ber-
get 1990, Luesley et al 1990, Bigrigg et al 1990, Martin-Hirsch et al 2010). 
For cryotherapy, success rates for treatment of CIN 3 range from 77% to 
93% (Popkin et al 1978, Hatch et al 1981). Still, including all randomized 
controlled trials comparing all these techniques, no technique was supe-
rior to another in terms of success or failure rates, i.e. in terms of incidence 
of residual disease (Martin-Hirsch et al 2010). 
 Most persistent or recurrent CIN cases occur within 24 months of 
treatment (Flannelly et al 2001, Chew et al 1999). Recurrence rate of any 
CIN is elevated for 6 years after treatment of CIN; after that, no difference 
in CIN incidence appears between the treated and healthy women (Mel-
nikow et al 2009). Age at treatment (over age 40) (European Guidelines 
for Quality Assurance in Cervical Cancer Screening 2008, Melnikow et 
al 2009), involvement of margins (incomplete excision) (Andersen et al 
1990, Dobbs et al 2000, Flannelly et al 2001, Ghaem-Maghami et al 2007), 
high pre-conization hrHPV load (Park et al 2007), and presence of glandu-
lar disease (Soutter et al 2001) predict higher rate of CIN recurrence. Also 
high grade CIN and treatment with cryotherapy are clear risk factors for 
CIN recurrence (Melnikow et al 2009).
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6.3.3 Follow-up
According to current care guidelines, all women treated for CIN must be 
followed up (Finnish Current Care guidelines 2010). After treatment of a 
CIN 1 lesion, a PAP smear is taken after 6 months, along with an hrHPV 
test and colposcopy when needed. If the PAP smear appears normal and 
the hrHPV test is negative, a new PAP smear is taken after 24 months 
post-treatment. If this sample again appears normal, the woman may re-
turn to normal screening intervals.  If the first post-treatment PAP smear 
is abnormal, a new smear is required after an additional 6 months and 
then at 24 months post-treatment.
For women treated for CIN 2, CIN 3, or AIS, a colposcopy along with 
a PAP smear and an hrHPV test is performed 6 months after the treat-
ment. If all three appear normal, the next PAP smear is taken 24 months 
after the treatment and then annually until 5 years after treatment. Af-
ter this, the woman returns to 5-year interval screening. If any appears 
abnormal, a new colposcopy and PAP smear are performed after an ad-
ditional 6 months. If only a PAP smear and colposcopy are performed 
at 6 months after treatment, a new PAP smear, and colposcopy when 
needed, is performed after 12 months. If they again appear normal, an-
nual PAP smears are taken until 5 years after the treatment. After this the 
woman may return to normal screening intervals (Finnish Current Care 
guidelines 2010). These current care guidelines in Finland were first in-
troduced in 2006 and updated in 2010. At the time of treatment for the 
women in our data, some variation may have existed in the follow-up 
after the CIN treatment.
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6.4 Long-term outcomes after CIN treatment
From among studies concerning endpoints similar to ours, only those 
published before ours are considered here.
6.4.1 Cervical cancer incidence
Among 795 women treated for cervical carcinoma in situ with CKC, 
7 women (0.9%) were diagnosed with invasive cervical cancer within 5 
to 20 years after treatment (Kolstad and Klem 1976). A cancer registry-
based study from Sweden estimated the cervical cancer incidence after 
CKC of cervical carcinoma in situ to be roughly 2.5 times as high for 20 
years among the treated compared to the general population (Pettersson 
and Malker 1989). In a Swiss study in which women treated for cervical 
carcinoma in situ were compared to a general population, the standard-
ized incidence ratio (SIR) for cervical cancer was 3.4 (p<0.01) (Levi et al 
1996). Another study with cytological and hospital-based follow-up found 
the incidence of cervical cancer to be elevated regardless of treatment 
method and after treatment of CIN 1 or 2 as well, and concluded that the 
incidence of cervical cancer after treatment of CIN was 5.8/1 000 women 
or 85/100 000 woman years (Soutter et al 1997).
A study of 843 women treated with cryotherapy with follow-up of at 
least 5 years reported one cervical adenocarcinoma at 6 years, suggesting 
a cumulative rate of invasive cancer of approximately 1.2 per 1 000 women 
(Benedet et al 1987). A study of 1 053 women treated mainly for CIN 3 
with laser conization showed a cumulative rate of invasive disease of 4 per 
1 000 women by 6 years with 6 540 woman-years of follow-up time and an 
overall rate of 61 per 100 000 woman years (Skjeldestad et al 1997). 
Soutter et al (1997) estimated the overall cervical cancer-preventive 
effect of CIN treatments to be 95%, based on progress rates of different 
grades of CIN from one unethical study, in which some women with 
CIN were left untreated and followed up for cancer incidence (McIn-
doe et al 1984).
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6.4.2 Other than cervical cancer incidence
Some evidence of increased other-cancer incidence after treatment of 
CIN already existed before the beginning of our study. After treatment of 
CIN 3, especially the anogenital cancers, cancers of the vagina, vulva, and 
anus, which share the same risk factor HPV, were more common than in 
the general population (Hemminki et al 2000a). Increased risk for cancers 
of major tobacco-related sites (lung, mouth or pharynx, esophagus, and 
urinary bladder) were also increased after CIN 3 diagnosis (Levi et al 1996, 
Hemminki et al 2000a, Evans et al 2003).  Cancers of the upper aerodiges-
tive tract and pancreas (Hemminki et al 2000a), as well as non-melanoma 
skin cancers (Levi et al 1996) were increased after treated CIN 3 as well. 
Tonsillar cancer incidence was 2.4-fold among women over 50 at the time 
of CIN 3 diagnosis (Hemminki et al 2000b). No studies were found of other 
than cervical cancer incidence according to grade of CIN or method of 
treatment.
6.4.3 Mortality
A Finnish study by Hakama et al (2004) reported overall mortality to be 
higher among women treated for cervical carcinoma in situ than for the 
general population. The risk of death was increased only at advanced 
ages and was independent of age at diagnosis of carcinoma in situ. To our 
knowledge, no other studies on mortality after treatment of any grade of 
CIN exist.
6.4.4 Fertility and pregnancy outcome
Treatment of CIN can cause scarring of the cervix and removal of cervi-
cal mucus-secreting cells (Hammond et al 1990, Kennedy et al 1993). The 
scarring may result in cervical stenosis (Baldauf et al 1996) and prevent 
sperm from entering the uterus or cause alterations in the cervical mu-
cus and therefore infertility. The loss of cervical mucus-secreting glands 
may compromise the cervical immune defense and thus predispose to 
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ascending infection and to premature prelabor rupture of the fetal mem-
branes (pPROM) and even to tubal infertility (Hammond et al 1990, Fox 
and Cahill 1991). Cervical stenosis occurs in 2 to 37% of women treated for 
CIN, depending on the treatment modality (Martin-Hirsch et al 2010).
Studies of adverse pregnancy outcomes after treatment of CIN are 
vast. The two largest meta-analyses so far, both comparing incidence of 
adverse pregnancy outcomes between the treated women and the general 
population, concluded that excisional treatment methods (CKC, LLETZ, 
and laser conization) are associated with preterm delivery (<37 gesta-
tional weeks) and low birth-weight (Kyrgiou et al 2006, Arbyn et al 2008). 
LLETZ was also associated with premature prelabor rupture of the fetal 
membranes (pPROM), and CKC with increased incidence of caesarean 
section in successive pregnancies. No such associations were observed af-
ter the ablative treatment methods (laser vaporization and cryotherapy). 
CKC was also associated with increased perinatal mortality, and severe or 
extreme pre-term birth (Arbyn et al 2008). In that meta-analysis, LLETZ 
and ablative treatment methods were not associated with these serious 
adverse pregnancy outcomes (perinatal mortality, severe or extreme pre-
term birth, and birth-weight <2 000g) (Arbyn et al 2008). A more recent 
study, comparing incidence of pPROM and spontaneous preterm deliv-
ery after different treatment methods, found no differences between the 
methods used, however (Shanbagh et al 2009). The depth of cone removed 
has been associated with increased risk for spontaneous preterm delivery 
in recent studies (Noehr et al 2009, Jakobsson et al 2009B). The proportion 
of the volume of cervix excised varies significantly, and is directly associ-
ated with the proportional deficit cervix volume at 6 months (Founta et al 
2010).
A retrospective cohort study from New Zealand compared deliveries of 
women treated for CIN to those of women referred to a colposcopy clinic 
but not treated for CIN. This study collected information about the smok-
ing status, their socioeconomic status, number of pregnancies, and order 
of the current pregnancy; and differentiated between types of preterm de-
livery (spontaneous preterm delivery, pPROM, medical induction). They 
observed CIN treatment (LEEP or laser conization) not to increase the risk 
for total or spontaneous preterm delivery. After LEEP and laser coniza-
tion, however, risk for pPROM was increased, especially with increasing 
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size of the cone (Sadler et al 2004). When women treated for CIN were 
compared to themselves before the treatment in terms of pregnancy com-
plications, the treated women were at only slightly higher risk for pre-term 
birth (Bruinsma et al 2007). Furthermore, when all possible relevant con-
founding factors (history of one or more induced abortions, two or more 
miscarriages, illicit drug use during pregnancy, having a major maternal 
medical condition, being single, and being of older maternal age) were 
adjusted for, only needle diathermy, NETZ, was associated with increased 
incidence of pre-term birth (Bruinsma et al 2007). 
A study using the Medical Birth Registry of Norway (all births between 
1967 and 2003) concluded that women with CIN are at significantly in-
creased risk for any pre-term delivery after the conization compared to 
the period before the conization (Albrechtsen et al 2008). No stratification 
between different methods of treatment or time-period was performed. 
A Finnish cohort of women treated with LLETZ identified similar find-
ings of increased post-treatment risk for pre-term delivery (Jakobsson et 
al 2009B). 
Because numerous studies, also using Finnish data, exist about the as-
sociation between CIN treatments and pre-term delivery, we decided not 
to study that association. Instead, studies about possible infertility after 
CIN treatment are scarce and based on small samples. One older review 
reported no impairment in fertility after CKC (Weber and Obel 1979). A re-
view concerning fertility after CIN treatment found no effect on future fer-
tility (Hammond and Edmonds 1990). One study documented pregnancy 
incidence to be the same after LLETZ and in the general population (Fer-
enczy et al 1995). Conversely, women treated with laser vaporization or 
excision had more pregnancies and deliveries after than before that treat-
ment (Spitzer et al 1995). Two studies about future fertility after LLETZ 
using a postal questionnaire concluded that the treatment had no effect 
on future fertility (Bigrigg et al 1994, Cruickshank 95). No increase was ob-
served in IVF pregnancies after the treatment of CIN, also indicating the 
treatment did not compromise future fertility (Jakobsson et al 2008). 
Nor has the miscarriage rate has increased among treated women 
(Weber and Obel 1979, Spitzer et al 1995, Tan et al 2004), but older stud-
ies of post-CKC pregnancies saw some increase in spontaneous first and 
second trimester abortions (Lee 1978, Jones et al 1979). Some evidence 
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about the association exists between increased rate of induced abortions 
and cervical cancer or dysplasia (Parazzini et al 1989, Wang and Lin 1995, 
Spitzer et al 1995). Spitzer et al (1995) concluded that women might have 
been worried about progression of their disease and therefore request-
ed more induced abortions. Ectopic pregnancies were in one study not 
more common after than before laser ablation or excision of CIN (Spitzer 
et al 1995). The risk of late abortion was, however, increased threefold 
compared to that of a healthy population among women treated for CIN 
(Albrechtsen et al 2008).
Possible factors associated with fertility and parturition after a CIN di-
agnosis are the anxiety and distress associated with discovery and treat-
ment of CIN (Marteau et al 1990, Le et al 2006). Concern about cancer, loss 
of attractiveness, loss of sexual functioning, anxiety, and low self-esteem 
are reported to exist both before and after colposcopy and punch-biopsy 
(McDonald et al 1989). One study of women referred to colposcopy and bi-
opsy reported their “spontaneous interest in sex, frequency of intercourse, 
and sexual arousal to be statistically significantly lower at 6 months com-
pared with the first visit, and at 2 years, spontaneous interest in sex and 
frequency of intercourse still remained low.” (Hellsten et al 2008). 
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7. Aims of the study
The aim of this study was to evaluate long-term cancer incidence, mor-
tality, and reproductive health among women treated for cervical intra-
epithelial neoplasia. Based on the results, we evaluated the efficacy and 
safety of CIN treatment practices, as well as the role of risk factors for other 
medical conditions of these women.
 
 1. To determine the effectiveness of CIN treatments in terms of 
  differences in cervical and other cancer incidence among women 
  treated for CIN, with particular emphasis on HPV- and 
  smoking-related primary sites.
 2. To determine whether histopathological grade, age at treatment, and
  method of treatment affect the success of the treatment in terms of
  disease-free survival after subsequent CIN 3, cervical cancer, 
  or other cancers. 
 3. To determine the efficacy of the CIN treatments by studying possible
  differences in cervical cancer mortality between the treated and 
  the reference cohort, and to determine the influence of the other risk 
  factors of women with CIN in terms of HPV- associated cancer, 
  other cancers, and overall mortality.
 4. To evaluate whether treatment of CIN has any effect on future 
  fertility and pregnancy outcomes, i.e. whether there exist differences 
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  in becoming pregnant and in giving birth, and in the incidence 
  of induced abortions, or of abnormal pregnancy (spontaneous 
  abortion, extra-uterine pregnancy, or molar pregnancy) 
  between women treated for CIN and their reference population.
Studying all these long-term outcomes among women treated for CIN 
would help with decisions as to whom to treat and when, for how long, 
and how to follow up after treatment. Most of all, do these treatments 
prevent cancer and reduce mortality, and are they safe for the women in 
terms of future fertility?
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8 Materials and Methods
8.1 Data sources, data work and study populations
All four studies are based on data concerning women treated for CIN at 
Helsinki University Central Hospital, Finland. This hospital was a major 
reference center in the Helsinki-Uusimaa region for women referred to 
colposcopy between 1974 and 2001. For each patient name, a unique per-
sonal identifier (PID), date and method of treatment (cold knife coniza-
tion, cryotherapy, laser conization or vaporization or LEEP), and diag-
nosis on the basis of histopathology (CIN 1–3 or CIN NOS, CIN NOS for 
dysplasias diagnosed before the grading to CIN 1–3) came from hospital 
records. The women included had squamous cell cervical lesions treated 
with these conservative methods.
This primary data included a total of 22 985 visits of 7 600 patients and 
was further screened for any possible double visits (same visit recorded 
twice) or inadequate social security numbers. After this, the data com-
prised 22 939 visits or treatments of 7 599 women. These data were linked 
with the Finnish population registry to assure the correctness of social se-
curity numbers, to determine the possible time of death, and the possible 
date of emigration. Further excluded were 19 (0.25%) patients and 42 vis-
its (0.18%), leaving 7 580 women for the final study population. We chose 
to use date, diagnosis, and method of treatment at the first visit for each 
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woman in all further analyses due to insufficient hospital data regarding 
possible follow-up visits. The research protocol of this study has been ap-
proved by the Ethics Committee, Section for Obstetrics and Gynaecology 
in the Helsinki-Uusimaa Hospital District.
8.1.1 Study I
The final study population, including 7 580 women and 22 898 visits, was 
linked to the Finnish Cancer Registry to identify cases of cervical cancer, 
other gynecological cancers, and any other cancers. In this procedure a 
further 16 patients were excluded due to a follow-up time of less than 6 
months, leaving a total of 7 564 patients for the cancer analysis (Table 2). 
The treatment for CIN was cold knife conization (CKC), laser va-
porization or conization, cryotherapy or LEEP, depending on year of 
treatment. The histopathological diagnosis at the treatment was CIN 1 
(n=2 446), CIN 2 (n= 1 543), CIN 3 (n=1 334), or CIN not otherwise speci-
fied (CIN NOS) (n=2 241). 
The follow-up of cancer incidence began 6 months after the first visit, 
and lasted until death, emigration, or 31 December 2003. We set the lag 
period of 6 months before possible diagnosis of invasive cervical cancer 
to exclude cancers already present at the initial visit.  
Age group Number of 
patients
Time of follow-up (woman-years)
0.5–9 10–19 Overall
< 29 3 114 14 018 424 – 14 441
30–44 2 958 26 829 15 600 795 43 225
45–59 1 074 10 611 12 554 4 303 27 468
60–74 347 3 704 4 572 1 801 10 077
71 773 1 142 430 2 345
Total 7 564 55 934 34 291 7 330 97 556
20+
75 +
Table 2 Number of women by age group according 
to duration of follow-up time in woman-years.
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8.1.2 Study II
The primary data from Study 1, the 
7 564 women treated for CIN, were 
linked with the updated Finnish 
Cancer Registry. Women diagnosed 
with invasive cervical, vaginal, vul-
var or lung cancer before, or within 
180 days of initial treatment, were 
excluded from the final analysis. 
Women who died or emigrated be-
fore or within 6 months after diag-
nosis were also excluded, compris-
ing a further 98 women. Thus 7466 
patients entered the survival analy-
sis (Table 3).
The follow-up of cancer inci-
dence and overall survival started 
6 months after CIN treatment and 
lasted until the date of cancer diag-
nosis, or the date of death, the 31st 
December 2003, or at the date of 
emigration. The proportional haz-
ard assumption was tested (Schon-
feld 1982) for both specific variables 
and globally.
8.1.3 Study III
The primary data, including dates 
of death or emigration from the 
woman’s first linkage to the Finn-
ish population registry, was again 
linked to the Finnish population registry to retrieve a reference population 
of five control women for each woman treated, individually matched by 
Reprinted from Kalliala I, Nieminen P, Dyba T, 
Pukkala E, and Anttila A. Cancer free survival 
after CIN treatment: comparisons of treatment 
methods and histology. Gynecologic Oncology 
2007;105:228–233, with permission from 
Elsevier.
Age at 
diagnosis
Number of
women
Follow-up
years
0–15 7 89
16–30 3 411 47 784
31–45 2 744 36 159
46–60 959 12 434
61–75 294 3 442
51 37776+
Grade of
CIN
Number of
patients
Follow-up
years
CIN 1 2 440 34 383
CIN 2 1 541 11 199
CIN 3 1 258 13 971
CIN NOS 2 227 40 731
Method of 
treatment
Number of
patients
Follow-up
years
CKC 724 18 566
Cryo 488 11 181
Laser 3 104 53 464
LEEP 3 150 17 072
Total 7 466 100 284
Table 3 Number of women 
according to age at diagnosis, 
initial histopathological grade of 
CIN, and method of treatment.
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age and municipality at the time of CIN treatment. Birth dates of children 
were also gathered simultaneously when available. To identify cases of 
cancer, the whole data set, including the reference population, was further 
linked to the Finnish Cancer Registry. 
Socioeconomic status came from Statistics Finland’s census records 
between 1970 and 2004 for all women. During that period the census was 
performed every 5 years, and the social class in the census performed 
nearest to the time of treatment was set as the social class for the final 
analysis. Classification of socio-economic status varied slightly over time, 
so occupational social classes were divided into six common non-hierar-
chical classes used at all points of measurement: (1) upper white collar, 
including entrepreneurs, employers and agricultural entrepreneurs, and 
employers (2) lower white collar, (3) blue collar workers including agri-
cultural workers (4) pensioners, (5) students over age 16, (6) housewives, 
the unemployed, and social class unknown. Children under were classed 
according to their parents. 
Causes of deaths in the data were gathered from Statistics Finland’s 
records from 1974 to 2005. The same ICD8-10 based longitudinal clas-
sification into 53 different possible causes of death was used throughout 
the study period. Deaths from cancers of the vagina, vulva, and anus were 
studied through Finnish Cancer Registry records because the classifica-
tion retrieved from Statistics Finland did not include these as separate 
causes of death. Deaths from cervical and uterine cancer were also further 
verified by use of linkage with the Finnish Cancer Registry.
Women with cervical cancer diagnosed before or within 6 months after 
the treatment of CIN, women whose socioeconomic status could not be 
retrieved, and women for whom no controls were available were excluded 
from the final data set. When a treated woman was excluded, her controls 
were excluded as well. After all exclusions, 7 104 women treated for CIN 
and 35 437 reference women were included in the final data set (Table 4).
The follow-up of mortality started for both the treated and reference 
population on the day the CIN was treated and ended at death or emigra-
tion, or on December 31, 2005. Based on a potential association with CIN, 
we grouped all 56 possible causes of death into 23 categories. We put extra 
emphasis particularly on the HPV- and smoking-related causes of death, 
and estimated the most common causes of death as well.
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8.1.4. Study IV
For the fertility study, the primary data consisting both of women treated 
for CIN and the reference population were linked with THL (National 
Institute for Health and Welfare) Care Registers for Social Welfare and 
Health (previously called STAKES Hospital Discharge Register) to retrieve 
the precise times of other pregnancy outcomes (spontaneous abortions, 
extra-uterine pregnancies, molar pregnancies, and induced abortions). 
Live births were already retrieved from the Finnish population registry. 
Information on possible sterilization came from a separate THL Steriliza-
Total
Number of 
CIN patients
Number of 
reference
population
Median age
at the start
of follow-up
Time of
follow-up
Average 
time of
follow-up
7 104 35 437 32 628 071 14.8
Grade of CIN
CIN 1 2 229 11 111 30 199 134 14.9
CIN 2* 3 700 18 478 32 343 946 15.5
1 175 5 848 35 84 990 12.1CIN 3
Age at treatment
14–39 5 029 25 096 29 446 834 14.8
40–59 1 689 8 431 46 153 409 15.2
386 1 910 66 27 828 12.160–89
Socioeconomic status
1 1 103 6 438 35 104 815 13.9
2 3 077 14 557 32 273 984 13.5
1 301 5 781 32 115 355 16.33
4 470 2 415 63 35 545 12.3
5 623 3 612 24 60 555 14.3
530 2 634 31 37 817 126
Copyright (2010)  Wiley. Used with permission from (Kalliala I, Dyba T, Nieminen P, Hakulinen T, Anttila A. 
Mortality in a long-term follow-up after treatment of CIN. Int J Cancer. 2010; 126: 224-31) Wiley.
*CIN NOS is included in CIN 2.
Table 4 Number of women in the treated and the reference cohort.
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Table 5 Number of women overall and according to 
pregnancy outcomes after and before the treatment of CIN.
CIN 1
Total*
CIN 2
CIN 3
CKC
Cryo
Laser
LEEP
Reference
population
Treated
women
36 615
1 983
3 183
1 013
414
399
2 654
2 712
30 436
6 179
26 335
1 687
2 760
525
198
451
2 834
1 968
21 363
4 972
38 963
2 006
3 941
1 445
657
444
2 894
2 947
32 021
6 942
21 174
1 284
2 073
403
121
313
2 121
1 205
17 414
3 760
30 900
1 493
2 587
1 120
618
351
2 172
2 059
25 700
5 200
941
66
94
11
13
27
110
21
770
171
1 009
64
94
35
3
7
79
104
816
193
N
pregnan-
cies
after
treatment
pregnan-
cies
before
treatment
deliveries
after
treatment
deliveries
before
treatment
spon-
taneus
abortions
after
treatment
spon-
taneus
abortions
before
treatment
CIN 1
Total*
CIN 2
CIN 3
CIN 1KC
Cryo
Laser
LEEP
Reference
population
Treated
women
374
27
75
5
CIN 1 7
18
79
3
267
107
474
26
59
20
CIN 1 2
8
51
44
369
105
295
12
35
6
0
2
38
13
242
53
196
10
18
10
0
1
5
32
158
38
3 551
298
483
100
57
91
486
247
2 670
881
6 384
413
733
260
34
77
587
708
4 978
1 406
extra 
uterine
pregnan-
cies after 
treatment
extra
uterine
pregnan-
cies before
treatment
molar
pregnan-
cies after
treatment
molar
pregnan-
cies before
treatment
induced
abortions
after
treatment
induced
abortions
before
treatment
* Total means overall number of women both in treated and the reference populations
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tion Registry, and induced abortions furthermore from the THL Abortion 
Registry. Data on all these pregnancy outcomes was reliably available only 
from January 1, 1974 forwards. Only singleton pregnancies were included 
in this study due to the differing nature of multiple fetuses.
We estimated the onset of pregnancy by median estimates of the dura-
tion of pregnancy for the outcome in question: 1) delivery; 280 days before 
the actual birth date, 2) spontaneous abortion and induced abortion; 63 
days before, 3) extra-uterine pregnancy; 56 days before, 4) molar pregnan-
cy; 77 days before. 
Women over age 50 at the time or sterilized before the CIN treatment 
were excluded from all analyses. The data were again linked to the Finn-
ish Cancer Registry to exclude all women diagnosed with invasive cervical 
cancer before or within 6 months after the initial treatment of CIN. Alto-
gether 233 women with cervical cancer meeting these conditions were 
excluded during this process. Women under 15 at the time of treatment 
entered the follow-up when they turned 15. After all exclusions, 36 615 
women (6 179 women treated and 30 436 control women) entered the sta-
tistical analysis (Table 5).
8.2 Statistical analysis
8.2.1 Study I
The possible differences in cervical and other cancer incidence between 
the treated women and the general population were calculated by com-
paring ratios of observed numbers to expected numbers of cancer cases 
(standardized incidence ratio, SIR). The 95% confidence intervals were 
calculated presuming that the number of cases observed followed a Pois-
son distribution. The expected numbers of cancer cases were stratified by 
sex, 5-year age groups, and 5-year calendar periods, based on the cancer 
incidence rates of southern Finland.
Cancer endpoints for the analysis were selected before the start of anal-
ysis, based on current knowledge of the etiology of cervical lesions. The 
risk for overall cancer, breast cancer, gynecological cancers, and of major 
smoking-related cancers, lung cancer, cancers which strongly correlate 
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with smoking (cancers of the larynx, tongue, mouth, other larynx besides 
naso- or hypopharynx, pancreas, bladder, and kidney) were calculated. 
8.2.2. Study II
Differences in disease-free survival or overall survival between the treat-
ment methods or CIN grades were assessed using the Cox proportional 
hazards regression model (Cox 1972).
The main outcomes studied were cervical cancer and the two other 
gynecological cancers (vulva, vagina) with a similar etiologic risk factor 
(HPV). We also estimated CIN 3, CIN 3+, overall cancer, and lung cancer-
free survival, as well as overall survival. To control for confounding factors, 
all models were adjusted for age of woman at treatment and further strati-
fied for the method of treatment and the grade of CIN. 
8.2.3. Study III
We used the Cox proportional hazards model (Cox 1972) to assess the dif-
ferences in survival between women treated for CIN and the reference 
population. Each matched set was defined by one woman treated for CIN 
and her five controls, matched with respect to age and place of residence 
at the beginning of follow-up. We compared hierarchical models using 
log-likelihood ratio statistics and tested the proportional hazard assump-
tion (Schonfeld 1982), both for specific variables and globally for the final 
models. If the proportionality assumption was not fulfilled, a stratified Cox 
analysis with respect to socioeconomic status was performed, which al-
ways led the model fulfilling the assumption. 
Final models were adjusted for socio-economic status, method of 
treatment, and grade of CIN.
8.2.4. Study IV
In all analyses, the incidence of deliveries, spontaneous abortions, extra-
uterine pregnancies, molar pregnancies, induced abortions or any type of 
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pregnancy (fertility) were calculated over the given follow-up time for the 
treated women and their reference population. The differences between 
risks were reported as hazard ratios (HR), and p-values less than 0.05 were 
considered significant.
The endpoints in the analysis were defined as follows: delivery means 
delivery over 24 weeks of gestation of a live-born baby; spontaneous abor-
tion means spontaneous abortion before 23 gestational weeks; extra-uter-
ine pregnancy means pregnancy outside the uterus, e.g. in fallopian tube, 
ovary, or abdominal cavity; molar pregnancy means benign gestational 
trophoblastic neoplasia; and induced abortion means medically per-
formed abortion, either with medication or by dilatation and curettage. 
Fertility denotes incidence of all endpoints: deliveries, induced abortions, 
extra-uterine pregnancies, spontaneous abortions, and molar pregnan-
cies.
We performed the main analysis of the data using a stratified Cox-
regression model (Cox 1972).  Follow-up began on the day of CIN treat-
ment and ended 1) at the start of the first-ever post-treatment pregnancy 
(referred to later as COX1 analysis), 2) at the onset of first pregnancy of a 
particular type (e.g. the first extra-uterine pregnancy or the first delivery), 
regardless of how many post-treatment pregnancies preceded the first par-
ticular type of pregnancy (referred to later as COX2 analysis), or at steril-
ization, turning 50, emigration, death, or 31 December 2004. The analysis 
of all post-treatment pregnancies was performed with Poisson regression 
(Breslow and Day 1987) with the same conditions for follow-up. 
In order to control for any possible confounding effect on their post-
treatment fertility, number of any pregnancies (0, 1, 2, 3+) and children 
(0, 1, 2, 3+) before treatment for CIN, and whether the type of pregnan-
cy in question had already occurred before the treatment were included 
in the models. Separate models specific to age at treatment (15–29 and 
30–50 years), number of children before treatment (0 and 1+), grade of 
CIN (CIN 1–3), and method of treatment (CKC, cryotherapy, laser, LEEP 
were also performed). For Poisson models, extra adjustment was made 
for municipality and age at time of CIN treatment, and by year of treat-
ment. Separate models were also fitted specifically to the number of chil-
dren (0/1+) before CIN treatment. To monitor for any possible change in 
the hazard ratios over time, Cox models with different lengths of follow-up 
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were fitted as well. 
We fitted a Cox regression model also for a subset of data, women born 
1958 or later. In this subset, all pregnancies before the treatment possibly 
influencing their future fertility were included, because data on reproduc-
tive endpoints in the registers used were available from January 1, 1974. 
Because these results were very similar to the results with the whole data 
set, the whole data set was used for all analyses. 
To monitor whether fertility rates between treated women and their 
reference population differed before treatment of CIN, a Poisson regres-
sion model of the number of different sites of pregnancy before the treat-
ment was performed. The follow-up began when the woman turned 15 or 
on January 1, 1974 (no information on pregnancies prior to this date were 
available) and ended at the date of CIN diagnosis. All models were ad-
justed for the woman’s age, municipality, and the year of upcoming CIN 
treatment. 
48
9. Results
9.1 Cancer incidence
9.1.1 Cervical cancer incidence 
Altogether 22 cases of cervical cancer were observed among the 7 564 
women treated for CIN, SIR 2.8, 95% CI 1.7–4.2, compared to the general 
population. Eleven cases were diagnosed 0.5 to 9 years after treatment, 
SIR 2.7 (CI 1.4–4.8), ten after 10 to 19 years, SIR 3.1 (CI 1.5–5.7), and one 
after 20 years, SIR 1.4 (CI 0.04–8.0). CIN 1 and CIN 2 lesions were associ-
ated with the highest risk for developing into invasive cervical cancer, 
SIRs 3.1 (CI 1.4–6.2) and 3.7 (CI 0.8–10.9), respectively (Table 6).
When CKC was set as the reference method, the HRs for cervical can-
cer incidence were 0.37 (CI 0.07–1.86) for laser, 0.44 (CI 0.09–2.23) for 
cryo, and 0.32 (CI 0.06–1.57) for LEEP. In comparing all colposcopically 
guided methods (cryo, laser, and LEEP together) against CKC, the HR 
for cervical cancer-free survival was 0.37 (CI 0.12–1.18). No clear differ-
ences were evident between different grades of CIN in cervical cancer-
free survival. Adjusted by histology and method of treatment, the HR 
for age at first visit in terms of cervical cancer-free survival was 1.37 (CI 
1.01–1.86).
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9.1.2 CIN 3 / CIN 3+ incidence 
Our material comprised 79 CIN 3+ cases. In CIN 3– or CIN 3+ (CIN 3 
or invasive cervical squamous cell cancer, ICC) -free survival, a clear 
trend emerged toward CKC being the least effective method of treat-
ment. The hazard ratios for CIN 3, when CKC was set as the reference 
method of treatment, were 0.21 (CI 0.06–0.74) for laser, 0.55 (CI 0.21–
1.47) for cryo, and 0.30 (CI 0.12–0.77) for LEEP. The hazard ratios for 
CIN 3+ when CKC was set as the reference method of treatment were 
0.25 (CI 0.09–0.67) for laser, 0.50 (CI 0.22–1.15) for cryo, and 0.27 (CI 
0.12–0.62) for LEEP.
When colposcopically guided methods together (cryo, laser, and 
LEEP) were compared to CKC, the HR for CIN 3 with CKC as the refer-
ence method of treatment, was 0.33 (CI 0.16–0.71), and for CIN 3 +, 0.32 
(CI 0.17–0.61).
The CIN 3+ free survival after CKC started to differ from other meth-
ods of treatment immediately, and continued to be such throughout 
the follow-up time of the study. No such effect was observed after the 
other methods of treatment.
Table 6 Cervical cancer incidence after treatment of CIN; overall, 
and according to the length of follow-up and grade of histology.
Overall 22 8.0 2.8 1.7–4.2
0.5–9 years 11 4.1 2.7 1.4–4.8
10–19 years 10 3.2 3.1 1.5–5.7
1 0.7 1.4 0.04–8.0
8 2.6 3.1 1.4–6.2
CIN 2 3
Observed Expected SIR 95% CI
CIN 1
20    years+
CIN 3
CIN NOS
3
8
0.8
1.4
3.3
3.7
2.2
2.5
0.8–10.9
0.5–6.4
1.1–4.9
Adapted by permission from BMJ Publishing Group Limited. [Kalliala I, Anttila A, Pukkala E, Nieminen P. Risk of 
cervical and other cancers after treatment of Cervical intraepithelial neoplasia: a retrospective cohort study BMJ 
volume 331: pp 1183-1185. 2005]
50
9.1.3 HPV-related cancer incidence 
After treatment of CIN, significantly increased risks were observable for 
cancer of the vulva, SIR 4.1 (CI 1.5–8.9), vagina, 12.0 (CI 3.9–28.0), and 
anus, 5.7 (CI 1.2–17.0).
Compared to CKC, the HRs for HPV-related cancer (cancers of vul-
va, vagina, and cervix) incidence were 1.02 (CI 0.33–3.12) for laser, 0.49 
(CI 0.09–2.38) for cryo, and 0.31 (CI 0.07–1.38) for LEEP, with no clear 
differences in cervical-, vaginal- or vulvar cancer-free survival by his-
topathological grade of the CIN lesions either. The hazard ratio of age 
at treatment, adjusted for histology and method of treatment, in terms 
of HPV-related cancer-free survival (cervix, vagina, vulva) was 1.43 (CI 
1.11–1.85).
All colposcopically guided methods together (cryo, laser, and LEEP) 
were compared to CKC in cervical-, vulva-, and vaginal cancer-free sur-
vival, HR 0.60 (CI 0.22–1.62).
Reprinted from Kalliala I, Nieminen P, Dyba T, Pukkala E, and Anttila A. Cancer free survival after CIN treatment:
comparisons of treatment methods and histology. Gynecologic Oncology 2007;105: 228-233, with permission
from Elsevier.
Figure 4 CIN 3+ free survival by method of treatment
0 year
1.00
After different methods of treatment adjusted for age and histology
CKC
LEEP
Kryo
0.95
0.90
10 20 30
Laser
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9.1.4 Smoking-related cancer incidence 
The incidence of lung or tracheal cancer was elevated compared to that 
of the general population after treatment of CIN, SIR 2.5 (CI 1.9–3.5). We 
found a strong correlation between increased risk for lung cancer and 
long-time follow-up. Age at first visit adjusted by histology and method of 
treatment was a statistically significant variable for lung cancer incidence 
in the cancer-free survival analysis, HR 1.94 (CI 1.53–2.45). No difference 
emerged in lung cancer incidence between different grades of CIN.
Increased risk was also observed for other smoking-related cancers 
among women treated for CIN compared to the general population, SIR 
1.7 (CI 1.3–2.3).
9.1.5. Overall cancer incidence
We identified 448 cases of any cancer among the 7 564 women in Study 
I treated for cervical intraepithelial neoplasia — 96 more cases than ex-
pected, SIR 1.3 (CI 1.2–1.4). The standardized incidence ratios of overall 
cancer — the incidence of all cancers combined — increased linearly 
with time. 
Altogether 396 cases of any invasive cancer were found after treat-
ment of CIN among 7 466 women in the internal analysis (Study II) with 
no statistically significant difference in overall cancer incidence between 
CKC and all three colposcopically guided methods of treatment.
Age at time of CIN treatment adjusted by histology and method of 
treatment was a statistically significant variable in our cancer-free sur-
vival analysis, HR 1.71 (CI 1.60–1.84). No differences appeared in overall 
cancer incidence between different grades of histology.
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9.2 Cancer Mortality
9.2.1 Cervical cancer mortality
Among the 7 104 women treated for CIN who entered the mortality analy-
sis, only three deaths from cervical cancer emerged. Cervical cancer mor-
tality among CIN-treated women was not significantly increased, HR 1.5 
(CI 0.4–5.5), and 1.0 (CI 0.3–4.0) after adjustment for socio-economic sta-
tus (Table 7).
9.2.2 HPV-related cancer mortality
HPV-related gynecological cancer (cancers of cervix, vulva, vagina, or 
anus) mortality among treated women compared to control population 
mortality was, even though still based on small numbers (altogether 19 
cases), significantly increased, HRs 2.9 (CI 1.1–7.5), and 3.1 (CI 1.1–8.6) 
after adjustment for socio-economic status (Table 7).
9.2.3 Smoking-related cancer mortality
Mortality from lung cancer was increased both before and after adjust-
ment for socio-economic status, respectively HRs 2.8 (CI 1.8–4.2) and 2.7 
(CI 1.8–4.1), and was constantly increased throughout the follow-up. Mor-
tality from the other smoking-related cancers was not elevated above that 
of the reference cohort, however.
9.2.4 Any cancer mortality
Overall cancer mortality among the CIN-treated was significantly in-
creased before and after adjustment for socio-economic status, HRs 1.4 
(CI 1.2–1.7) and 1.4 (CI 1.2–1.7), respectively (Table 7).
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9.2.5 Overall mortality
Overall follow-up of mortality was 628 017 woman-years, on average 14.8 
years / woman. Overall mortality was 20% higher among treated women, 
HR 1.2 (CI 1.1–1.3), and 1.1 (CI 1.0–1.3) after adjustment for socio-eco-
nomic status (Table 7).
Among women less than 40 years old at the time of treatment the over-
all mortality was significantly higher in the treated cohort than among the 
reference population, but those over 40 at treatment showed no statisti-
cally significant difference in overall mortality between groups. 
No statistically significant difference appeared in overall cancer inci-
dence or overall survival between CKC and all three colposcopically guid-
ed methods of treatment. With CIN 1 as the reference, the HRs for overall 
survival were 0.91 (CI 0.60–1.37) for CIN 2, 0.94 (CI 0.72–1.23) for CIN 3, 
and 0.95 (CI 0.66–1.37) for CIN NOS.
9.3 Fertility and Pregnancy outcome
9.3.1 Fertility (Table 8)
Overall, 2 578 women treated for CIN and 11 642 women in the control 
population became pregnant during 258 098 woman-years of follow up. 
Table 7 Numbers of deaths among treated women versus the reference population.
*Cancers of the uterine cervix, vulva, vagina, and anus
Copyright (2010) Wiley. Used with permission from (Kalliala I, Dyba T, Nieminen P, Hakulinen T, Anttila A. 
Mortality in a long-term follow-up after treatment of CIN. Int J Cancer. 2010; 126: 224-31) Wiley
Cervical cancer 3 9 1.5 (0.4–5.5) 1.0 (0.3–4.0)
HPV-related 
anogenital cancer* 8 11 2.9 (1.1–7.5) 3.1 (1.1–8.6)
Lung cancer 37 72 2.8 (1.8–4.2) 2.7 (1.8–4.1)
195 686 1.4 (1.2–1.7) 1.4 (1.2–1.7)
530 2 251 1.2 (1.1–1.3) 1.1 (1.0–1.3)
Deaths after
treatment 
for CIN
Deaths, 
reference 
population HR and 95% CI
HR and 95% CI
adjusted for 
socioeconomical
status
Overall mortality
All cancers
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The incidence of any type of pregnancy after treatment (fertility) among 
women treated for CIN was 20% higher than that for the control popula-
tion for the first post-treatment pregnancy; adjusted HR 1.20 (p<0.001). 
The incidence of any pregnancy among treated women with no children 
before treatment was significantly elevated, adjusted HR 1.29 (CI 1.22–
1.39), but among treated women with one or more children prior to treat-
ment it was not; HR 1.09 (CI 0.99–1.20).
The HR for any pregnancy after treatment for CIN (not only the first 
pregnancy) among women treated for CIN compared to the reference 
population was 1.15 (p<0.001). Before treatment, the fertility of CIN pa-
tients was also elevated; HR 1.06 (p<0.001).
No elevation in hazard ratio of any endpoint occurred immediately af-
ter the treatment for CIN.
9.3.2 Deliveries (Table 9)
Incidence of deliveries in the first post-treatment pregnancies among the 
treated women was significantly higher than for the control population; 
adjusted HR 1.12 (p<0.001).  For treated women with no children prior 
to treatment, the adjusted HR was 1.22 (CI 1.14–1.31), and for women al-
ready with one or more children, 0.92 (CI 0.82–1.03).
The incidence of at least one delivery after the CIN treatment among 
Number 
of treated
women 
pregnant
Number of 
reference
women
pregnant Adjusted HR* 95% CI p
First preg-
nancy after 
treatment
2 758 11 642 1.20 < 0.001
Overall 
fertility after 
treatment
4 972 21 363 1.15 < 0.001
Overall 
fertility before
treatment
6 942 32 021 1.06
1.15–1.26
1.11–1.18
1.04–1.09 < 0.001
Table 8 Numbers of women with at least one post-treatment pregnancy, 
and overall fertility after and before the treatment of CIN.
*adjusted for number of any pregnancies (0, 1, 2, 3+) and children (0, 1, 2, 3+) before treatment for CIN.
Fertility means incidence of any type of pregnancy.
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the treated women compared to that in the reference population was sig-
nificantly elevated: adjusted HR 1.10 (p<0.001).  For women with no deliv-
eries before treatment, the adjusted HR was 1.22 (p<0.001) and for women 
with at least one delivery before the treatment, 0.91 (p=0.08).
The adjusted HR among women treated for CIN compared to the ref-
erence population for delivery at any time after the treatment of CIN was 
1.07 (CI 1.03–1.11), higher than the incidence of deliveries before the CIN 
treatment: adjusted HR 0.99 (CI 0.96–1.02).
9.3.3. Spontaneous abortions (Table 10)
The adjusted HR for spontaneous abortions in the first post-treatment preg-
nancy was 1.04 (p=0.75) between the treated women and the reference pop-
ulation. The incidence of at least one spontaneous abortion was also slightly, 
but not significantly, higher among women treated for CIN: adjusted HR 
1.11 (p=0.10).
The adjusted HR for spontaneous abortion in all post-treatment pregnan-
cies was 1.08 (p=0.35). Spontaneous abortions were slightly elevated among 
the CIN patients before the treatment date, with adjusted HR 1.16 (p=0.07).
Adjusted HR* 95% CI p
First preg-
nancy after 
treatment
1 932 9 424 1.12 < 0.001
At least one
delivery after
treatment
2 206 10 382 1.10 < 0.001
Overall number 
of deliveries
after treatment
3 760 17 414 1.07
1.06–1.18
1.05–1.16
1.03–1.11 < 0.001
Overall number 
of deliveries
before 
treatment
5 200 25 700 0.99 0.96–1.02 0.53
Deliveries 
among
treated 
for CIN
Deliveries,
reference
population
*adjusted for number of any pregnancies (0, 1, 2, 3+) and children (0, 1, 2, 3+) before treatment for CIN, 
and whether the women had already delivered before treatment.
Table 9 Number of deliveries in the first post-treatment pregnancy, 
number of women with at least one delivery after the treatment, 
and overall numbers of deliveries after and before the treatment of CIN.
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9.3.4 Extra-uterine pregnancies (Table 11)
The adjusted HR for extra-uterine pregnancy in the first post-treatment 
pregnancy was 1.93 (p<0.001). For women with no children prior to the 
treatment and for women with at least one child before the treatment, 
the adjusted HRs were in the first pregnancy 2.22 (p=0.003) and 1.47 
(p=0.30), respectively. The incidence of at least one post-treatment extra-
uterine pregnancy was also elevated among the treated: adjusted HR 1.81 
(p= 0.003).
Overall adjusted HR for extra-uterine pregnancy was 1.88 (CI 1.50–
2.36) after treatment and 1.40 (1.13–1.74) before the treatment, with no 
significant difference.
9.3.5 Molar pregnancies
We observed 146 molar pregnancies — 26 among the treated and 120 in 
the reference population — in the first post-treatment pregnancy, and 295 
Adjusted HR* 95% CI p
First preg-
nancy after 
treatment
80 412 1.04 0.75
At least one
spontaneous 
abortion after
treatment
159 707 1.11 0.23
Spontaneous
abortions 
after
treatment
171 770 1.08
0.80–1.36
0.94–1.33
0.92–1.28 0.35
Spontaneous
abortions
before 
treatment
193 816 1.16 0.99–1.36 0.07
Spontaneous
abortions
among those 
treated
for CIN
Spontaneous
abortions, 
reference
population
Table 10 Spontaneous abortions in the first post-treatment pregnancy, 
number of women with at least one spontaneous abortion, and overall 
numbers of spontaneous abortions after and before the treatment of CIN.
*adjusted for the number of any pregnancies (0, 1, 2, 3+) and children (0, 1, 2, 3+) before the treatment for 
CIN, and whether the women had had a spontaneous abortion before the treatment or not.
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molar pregnancies overall after CIN treatment. The adjusted HR for molar 
pregnancy in the first post-treatment pregnancy was 1.04 (CI 0.80–1.36). 
The incidence of at least one molar pregnancy was slightly higher among 
women treated for CIN: adjusted HR 1.11 (CI 0.81–1.52). 
9.3.6 Induced abortions (Table 12)
The incidence of induced abortions in the first post-treatment pregnancy 
among the treated women was significantly elevated, adjusted HR 1.62 
(p<0.001). Hazard ratios for women with no children was 1.65 (CI 1.40–
1.94) and at least one child 1.83 (CI 1.49–2.24).
The incidence of at least one induced abortion was also elevated 
among the treated, the adjusted HR being 1.53 (p<0.001). The adjusted 
hazard ratios for at least one post-treatment induced abortion for women 
with no induced abortion and at least one induced abortion before the 
treatment were 1.70 (p<0.001) and 1.09 (p=0.58), respectively. The overall 
Adjusted HR* 95% CI p
First preg-
nancy after 
treatment
59 151 1.93 < 0.001
At least one
extra-uterine 
pregnancy
after 
treatment
89 229 1.81 < 0.001
1.35–2.76
1.40–2.34
Extra-uterine
pregnancies 
after 
treatment
107 267 1.88 1.50–2.36 0.005
Extra-uterine
pregnancies
before 
treatment
105 369 1.40 1.13–1.74 0.0002
Extra-uterine
pregnancies
among those 
treated
for CIN
Extra-uterine
pregnancies,
reference
population
*adjusted for number of any pregnancies (0, 1, 2, 3+) and children (0, 1, 2, 3+) before treatment for CIN, 
and whether the women had had an extra-uterine pregnancy before treatment.
Table 11 Extra-uterine pregnancies in the first post-treatment pregnancy, 
number of women with at least one induced extra-uterine pregnancy, and overall 
numbers of extra-uterine pregnancies after and before the treatment of CIN.
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HR for all induced abortions after CIN treatment was 1.54 (CI 1.43–1.66). 
Before the treatment date, induced abortions were already more common 
among those treated, HR 1.39 (CI 1.31–1.47), with no significant differ-
ence from the incidence observed after treatment.
Adjusted HR* 95% CI p
First preg-
nancy after 
treatment
481 1 535 1.62 < 0.001
At least 
one induced
abortion
after
treatment
695 2 245 1.53 < 0.001
1.45–1.82
1.40–1.67
Overall number
of induced 
abortions after
treatment
881 2 670 1.54 1.43–1.66 < 0.001
Overall number
of induced 
abortions 
before 
treatment
1 406 4 978 1.39 1.31–1.47 < 0.001
Induced
abortions
among those 
treated
for CIN
Induced
abortions,
reference
population
Table 12 Number of induced abortions in the first post-treatment pregnancy, 
number of women with at least one induced abortion, and overall numbers of 
induced abortions after and before the treatment of CIN.
*adjusted for number of any pregnancies (0, 1, 2, 3+) and children (0, 1, 2, 3+) before treatment for CIN, 
and whether the women had had an induced abortion before treatment.
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10 Discussion
10.1 Comparison of the results to those of other studies
10.1.1 Cervical cancer incidence
We observed in Study I that cervical cancer incidence was 2.8-fold high-
er among the treated than in the general population — about 22/100 000 
woman-years. Soutter et al (1997) concluded the incidence of cervical 
cancer after treatment of CIN to be 5.8/1 000 women or 85/100 000 wom-
an-years, and this incidence remained elevated for at least 8 years. In 
that study, the follow-up was performed via cytological samples, with 
no systematic follow-up after the treatment. This might have resulted in 
women with symptoms attending follow-up more frequently and there-
fore would explain the slightly higher incidence. Furthermore, the results 
of more recent studies are very much in line with our findings: The inci-
dence of cervical cancer after CIN treatment was about 2.8-fold higher 
than expected (Soutter et al 2006); SIR 2.3 compared to that of the gener-
al population after treatment of CIN 3 (Strander et al 2007); SIR 1.7 com-
pared to a general population (Jakobsson et al 2010); and cervical cancer 
incidence after CIN treatment 37/100 000 woman-years (Melnikow et al 
2009). The results in the studies including only cervical carcinoma in situ 
lesions did not differ from ours: SIR 2.3 to 3.4 compared to the general 
population figure after treatment of carcinoma in situ (Hemminki et al 
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2000a, Levi et al 1996); and 50/100 000 (Pettersson and Malker 1989).
When we studied the differences between the treatment methods and 
set CKC as the reference method, the hazard ratios for cervical cancer inci-
dence were 0.37 for laser, 0.44 for cryo, and 0.32 for LEEP. In comparing all 
colposcopically guided methods (cryo, laser, and LEEP together) to CKC, 
cervical cancer-free survival was 0.37 (95% CI 0.12–1.18). We observed a 
trend towards cryo’s being the worst of the three colposcopically assisted 
methods in terms of CIN 3+ incidence as well, but we lacked cases of inci-
dent cancers and therefore statistical power. In terms of CIN 3+ incidence 
in our study, CKC was clearly the worst method. Nor did another Finnish 
study published recently find any significant differences in cervical can-
cer incidence between the different treatment modalities (Jakobsson et 
al 2010). Melnikow et al (2009) found cryo to be significantly the worst in 
terms of cervical cancer incidence, OR 2.98, compared to other methods of 
treatment. That data included no women treated with CKC.
For different grades of CIN, Melnikow et al (2009) observed cervical 
cancer incidence to be increased to a greater extent after CIN 3 than after 
CIN 1 (OR 4.1), and for age over vs. under 40 at the time of CIN treatment 
diagnosis, the OR was 1.75. A clear difference was that we found no varia-
tion in CIN 3+ or cervical cancer incidences between different grades of 
CIN. This may be due to different classification of the lesions: We used the 
first diagnostic biopsy to categorize patients; for instance the lesions first 
treated as CIN 1 were called CIN 1 lesions throughout the follow-up in our 
data. The Melnikow group decided that the worst histological diagnosis in 
their analysis to appear within 6-month follow-up after the initial visit to be 
the index histology. This is evident in the distribution of CIN 1 cases in the 
two data sets: 19% of all CIN cases as CIN 1 cases for the Melnikow group, 
vs. 32% CIN 1 cases of all the CIN cases in our own data. This difference in 
proportion of CIN grades, due to differing classifications, might well explain 
this difference. Increasing age at treatment of CIN significantly raised our 
cancer incidence, to HR 1.4, a finding in line with the Melnikow group’s. 
Women treated for CIN of any grade by any treatment method are at in-
creased risk for cervical cancer, compared to the risk of the standard popu-
lation, for at least 20 years after the treatment. This suggests that women 
diagnosed with CIN 1 and 2 possess the same risk factors as do women with 
CIN 3, and therefore are equally at risk for invasive cancer. Still, screening 
61
for and treating cervical preinvasive lesions reduces the burden of invasive 
cancer significantly: We estimated the effect of CIN treatment in our data 
based on an earlier study of progression rates of CIN 3 lesions in Finland 
(Hakama and Räsänen-Virtanen 1976) that suggested 28 to 39% of cases 
of CIN 3, when left without treatment, would progress to invasive cancer. 
Another study, following women with cervical carcinoma in situ, reported 
that when left untreated, about 22% of the lesions would progress to inva-
sive cervical cancer (McIndoe et al 1984). We had 837 cases of CIN 3 le-
sions among women aged 30 to 59. Based on the Finnish estimate, 234 to 
326 cases would have developed into invasive cervical cancer, whereas we 
observed only three. The treatment effect therefore may have approached 
99%.
10.1.2 HPV-related cancer incidence
After treatment of CIN, we observed increased risks for cancer of the vulva 
(4.1, 95% CI 1.5–8.9), vagina (12.0, CI 3.9–28.0), and anus (5.7, CI 1.2–17.0). 
Few studies of other HPV-related cancer incidences after treatment of CIN 
were retrievable, and their results were very similar to ours. The point esti-
mates between the studies vary slightly, but women treated for CIN clearly 
are at increased risk for cancers of the vagina, vulva, and anus. 
A later Finnish study found somewhat similar increases in cancers 
at these primary sites (SIR 6.15 for cancer of the vulva, 9.08 for vaginal 
cancer, and 3.56 for anal cancer) (Jakobsson et al 2010).  A Swedish Can-
cer Registry-based study of women treated for CIN 3 published after ours 
found increased risk for cancers of the vagina (incidence relative risk, 
(IRR), 6.74, 95% CI 5.24–8.56), vulva (2.22, CI 1.79–2.73), and anus (4.68, 
CI 3.87–5.62) compared to risk in the general population (Edgren and 
Sparen 2007). An earlier study using the same database found cancers of 
the anus and female genitalia (including vagina, vulva, and unspecified 
cancer of uterus) to be increased similarly after treatment of cervical car-
cinoma in situ (Hemminki et al 2000a). Evans et al (2003) documented, as 
well, an increase in incidence of cancers of the anus (SIR 5.9), vulva (SIR 
4.4), and vagina (SIR 18.5) after treatment of CIN 3. 
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10.1.3 Smoking-related cancer incidence
Our study showed, after treatment of CIN, incidence of cancer of the lung 
or trachea compared to the general-population incidence was elevated 
(SIR 2.5, 95% CI 1.9–3.5). An increased risk was also observable for other 
smoking-related cancers (cancers of larynx, tongue, mouth, other larynx 
besides naso- or hypopharynx, pancreas, bladder and kidney) among 
women treated for CIN compared to the general population (SIR 1.7, CI 
1.3–2.3). A later Finnish study found a similar increase in incidence of 
smoking-related cancers (SIR 1.45 CI 1.12–1.86) (Jakobsson et al 2010). A 
study based on records of the Swedish Cancer Registry observed that after 
treatment of cervical carcinoma in situ, cancers of the lung (SIR 2.17) and 
urinary bladder (SIR 1.4) were increased (Hemminki et al 2000a). After 
treatment of cervical carcinoma in situ, SIR 2.2, cancers of the lung, mouth 
or pharynx, esophagus, and urinary bladder were more common than in 
the general population, in another study about treated cervical carcinoma 
in situ lesions (Levi et al 1996). Evans et al (2003) similarly found that inci-
dence of cancers of the lung (SIR 1.5) and kidney (SIR 1.6) was increased 
after treatment of CIN 3 (Evans et al 2003). 
All these results are from studies performed methodologically the 
same way as ours: comparison of a treated cohort with the incidence in 
the general population. Even though we also included women treated for 
CIN 1 and 2 lesions, the results obtained by other groups are very much 
in concordance with our observations. Women with CIN of any grade are 
documented to smoke more often than does the general population. Al-
though smoking is associated with increased risk for cervical cancer, its 
risk for developing other cancers is significant as well.
10.1.4 Mortality
To our knowledge, few studies about mortality after treatment of CIN ex-
ist. Due to the excellent registers in Finland, two of them were performed 
here as well. We observed no increase in cervical cancer mortality among 
treated women; HR 1.5, (CI 0.4–5.5), and 1.0, (CI 0.3–4.0) after adjusting 
for socio-economic status. In another Finnish study by Jakobsson et al 
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(2009a), the standardized mortality ratio (SMR) for cervical cancer was 
7.7 (CI 4.23–11.15). No information on socio-economic risk factors was 
included. No linkage between the CIN 3 cases gathered from THL and the 
Finnish Cancer Registry was performed by the Jakobsson group, leaving 
prevalent or earlier invasive cervical cancer cases in the data. This may at 
least partly explain our difference in cervical cancer mortality. When they 
later excluded cervical cancer cases from the data, their data still showed, 
for cervical cancer mortality, an increase (Personal communication with 
M Jakobsson). 
Mortality, SMR, from all diseases and medical conditions in the study 
by Jakobsson et al (2009a) was 1.13, 95% CI 1.01–1.26, from all cancers 
1.09 (CI 0.91–1.27), and from injury deaths 1.31 (CI 1.03–1.58). All-disease 
mortality, and mortality from accidents were practically identical in our 
results, as well. In these categories, in both studies, the cause of death 
came mainly from the Causes of Deaths Registry. Mortality from any can-
cer was somewhat lower than in our study 1.1 (0.9–1.3) vs. 1.4 (1.2–1.7). 
They had altogether 145 cancer deaths among almost 26 000 women; we, 
on the other hand, had 195 cancer deaths among 7 100 women, indicating 
a possible difference in duration of follow-up. The Jakobsson group pa-
per lacks total length of follow-up in woman-years. In our data, all cancer 
deaths were further verified from the Finnish Cancer Registry, and cancer 
deaths additional to those received from the Cause of Death Register did 
in fact emerge. Our study was based on treatments in one hospital, Hel-
sinki University Central Hospital. The study population of the Jakobsson 
group comprised women gathered from a nationwide registry. Perhaps 
these differences in design, follow-up time, and nationwide variation in 
the efficacy of the treatment and follow-up explain the differences be-
tween these results.
A study by Hakama et al (2004), reported excess mortality among 
women with cervical carcinoma in situ. Their risk of death (>10%) was 
substantially increased only at advanced ages and was independent of 
age at diagnosis. Our own difference in overall mortality between treated 
women and our reference cohort had a tendency to diminish, the older 
were the women when treated, but tended to increase between the two 
cohorts the longer was the follow-up time, thus supporting these earlier 
findings. 
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Despite effective treatment and follow-up, the mortality from other 
than cervical, and other than HPV-related cancers as well, is elevated 
among the women treated for CIN. Smoking, in particular, is associated 
with both cervical cancer and lung cancer, and women treated for CIN 
here had significantly increased lung cancer mortality. Women with any 
grade of CIN have other risk factors, in addition to HPV, which cause sig-
nificant morbidity and mortality; this should be taken into account when 
both evaluating and planning cervical cancer-preventive activity.
10.1.5 Fertility and pregnancy outcome
Earlier studies about fertility have not reported a significant reduction in 
fertility, or fertility has been higher in the treated cohort. One review of 
small, older studies concluded that no impairment in fertility had been 
observed after treatment of CIN (Hammond and Edmonds 1990). Based 
on a postal questionnaire of 250 women treated with LEEP, again no re-
duction in fertility was observed: This was during a 3-year follow-up (Big-
rigg et al 1994). Another cohort study comparing pregnancy outcomes 
of 433 women before and after treatment of CIN with laser conization 
concluded that the treated women actually had more pregnancies (277 
vs. 177, p<0.01); the mean duration of that study interval was 3.8 years 
(Spitzer et al 1995.) In a cohort of 574 women treated with LEEP, the in-
cidence of pregnancies was again slightly higher among the treated than 
in the general population (8.5/100 women vs. 7.4/100 women) (Ferency 
et al 1995). 
In our cohort of 36 000 women, for whom average duration of follow-
up was almost 15 years, we calculated the incidence of at least one preg-
nancy after the treatment, the incidence of all pregnancies before and 
after treatment, and the incidence of pregnancies in increasingly long 
follow-up periods after treatment. As all these outcomes were signifi-
cantly more common among the treated than in the reference popula-
tion, we can assume that the treatment causes neither reduction in fer-
tility right afterwards nor any infertility at all. The point estimates were 
actually higher after than before treatment, a finding in line with previous 
findings.
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The incidence of deliveries among the treated women in the first 
post-treatment pregnancy and in all post-treatment pregnancies was 
significantly increased, and more often than did women in the reference 
population, the treated women had at least one delivery. Our incidence 
of deliveries before the treatment was not increased. A study based on a 
postal questionnaire involving 653 women treated for CIN reported no 
difference in incidence of deliveries between the treated and a healthy 
reference cohort (Cruickshank et al 1995). Another study comparing the 
pregnancies of 433 women before and after treatment of CIN with laser 
conization observed a significantly higher incidence of deliveries after 
the treatment, 163 vs. 112 (p<0.01) (Spitzer et al 1995). This elevation in 
the post-treatment deliveries here and in the study of Spitzer et al may be 
due to the psychosocial effect of the treatment: Although it is documented 
that after the treatment for CIN women experience anxiety, distress and 
low self-esteem, and spontaneous interest in sex and frequency of inter-
courses have been reduced (McDonald et al 1989, Marteau et al 1990, Le 
et al 2006, Hellsten et al 2008), we observed no corresponding decrease 
in fertility. The treatment might have actually served as a “wake up call”: 
Despite the reduction in spontaneous interest in sex and in frequency 
of intercourse for a while after treatment, the urge to become a mother 
might have increased simultaneously. This is supported by findings that 
the post-treatment incidence of deliveries was significantly increased 
only among the women with no children prior to treatment. Psychosocial 
effects caused by the treatment are, in our opinion, the most likely expla-
nation behind the observed increase in the incidence of deliveries.
We observed no increase in incidence of spontaneous abortion among 
the treated women, with point estimates actually lower after than before 
treatment. Especially among women with at least one child before treat-
ment, we observed no significant difference in spontaneous abortion 
incidence. Nor did previous small studies find any increase in spontane-
ous abortion rates (Weber and Obel 1979, Tan et al 2004). Older studies, 
again based on small numbers of both women and endpoints, did find 
some increase in first and second trimester spontaneous abortions after 
CKC (Lee 1978, Jones et al 1979). We saw no such effect even after CKC. A 
Norwegian registry-based study, however, observed a three-fold increase 
in late spontaneous abortion incidence after any treatment of any grade 
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of CIN (Albrechtsen et al 2008). As we lacked knowledge of the exact 
pregnancy weeks in the spontaneous abortion data, our results are not 
directly comparable to those of Albrechtsen et al.
Only one previous study of extra-uterine pregnancy rates exists: For 
433 women treated with laser conization, their pregnancies were stud-
ied before and after treatment. No comparison to the general popula-
tion was made, and no observation of any increase in incidence of extra-
uterine pregnancies after treatment (Spitzer et al 1995). We observed an 
elevated incidence of extra-uterine pregnancies after treatment of CIN, 
both in the first post-treatment pregnancy and overall, and the treated 
women had at least one extra-uterine pregnancy more often as well. 
The incidence of ectopic pregnancies was already elevated before treat-
ment, however, and we observed no significant increase in incidence 
right after the treatment, a result in line with Spitzer et al (1995). Pre-
vious extra-uterine pregnancy is a major risk factor for another ecto-
pic pregnancy, so our results were adjusted for this event before treat-
ment. Genital infections, especially Chlamydia trachomatis, is a major 
cause of pelvic inflammatory disease (PID), and women with CIN are 
well documented to have a higher incidence of this infection than in 
the general population. Based on all of this, we can assume that other 
risk factors for PID and tubal damage that these CIN patients possess in 
excess when compared to the general population rather than the CIN 
treatment itself causes their higher post-treatment incidence of extra-
uterine pregnancies.
The incidence of induced abortions was increased among those 
treated, both before and after treatment of CIN. The treated women had a 
higher incidence of at least one induced abortion as well. Some evidence 
exists for an increased induced-abortion rate and cervical cancer or cervi-
cal dysplasia between the treated and a healthy population or occurring 
after than before treatment in the same cohort (Parazzini et al 1989, Wang 
and Lin 1995, Spitzer et al 1995). We observed a slightly higher, but not 
a statistically significant, incidence of post-treatment induced abortions, 
but no evidence whatsoever about the treatment per se as significantly 
elevating induced abortion incidence. The anxiety and distress caused by 
treatment might perhaps be expected to result for some individuals in an 
increased willingness to terminate pregnancies.
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10.2 Strengths and limitations
The follow-up in all four studies was based on nationwide registers: Can-
cer cases were retrieved from the Finnish Cancer Registry, causes of deaths 
were from Statistics Finland’s Cause of Death Register; dates of death, of 
emigration, and birthdays of children came from the Finnish Population 
Registry, and data on the endpoints concerning reproductive health, i.e. 
dates of induced and spontaneous abortions, extra-uterine pregnancies, 
molar pregnancies, and sterilizations from the THL (National Institute for 
Health and Welfare) Care Registers for Social Welfare and Health (previ-
ously called STAKES Hospital Discharge Register). The socioeconomic 
status of the women for Study III was retrieved from Statistics Finland’s 
census records between 1970 and 2004 (Sosioekonomisen aseman luoki-
tus 1989). The records in all these organizations are considered reliable for 
epidemiologic research (Keskimäki and Aro 1991, Teppo et al 1994, Gissler 
and Shelley 2002, Gissler and Haukka 2004), and the linkage procedures 
were precise and trustworthy in the current study. 
The number of women treated for CIN, the number of most endpoints, 
and the follow-up time in all four studies were superior to those in earlier 
studies. Earlier data showed, for instance, cervical cancer incidence to be 
increased after CIN treatment for 8 years (Soutter et al 1997), and on aver-
age we had a follow-up of 12 years per woman in Study I. 
The CIN cases were collected manually from paper- and microfilm ar-
chives for women treated for CIN as well as by a computerized database 
search of hospital records of Helsinki University Central Hospital, Depart-
ment of Obstetrics and Gynecology. Possible flaws in personal identifiers 
and other data in the registers used might predispose to bias. All personal 
identifiers were linked with the Finnish Population Registry to assure the 
correctness of the PIDs. Due to a wrong PID in the hospital records, a few 
women might actually have never been treated for CIN. This source of 
systematic bias can be considered minor and not affecting results signifi-
cantly.
The Finnish Cancer Registry has records of cervical carcinoma in situ 
cases from 1954 onwards and for CIN 3 cases from the mid 1990’s (Finn-
ish Cancer Registry 2009). No nationwide quality-assured register of 
CIN 1 and 2 cases exists for the whole follow-up time in our study. It is 
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thus possible that some women have actually been treated for CIN before 
appearing in the hospital records studied, and hence in our data. CIN is 
also a dynamic lesion: Most CIN 3 lesions obviously developed with time 
through CIN 1 and 2, and women who were diagnosed first with CIN 1 and 
later with cervical cancer might have, in between, been treated for CIN 2 
and CIN 3 as well. The diagnosis gathered from the hospital records might 
therefore have changed toward the worse or the better later on without 
our knowledge, and verification or information bias might thus arise, pos-
sibly affecting our results. We can still assume that the overall distribution 
of grades of CIN would remain the same. Furthermore, all women treated 
for CIN 1, 2, 3, and CIN NOS, share the same risk factors: HPV infection, 
smoking, early sexual debut, multiple sexual partners, and all women in 
our data were by definition diagnosed and treated for CIN. It is also pos-
sible that the initial diagnosis in hospital records was CIN, even though it 
is actually a question of an already invasive cancer, not revealed until later 
in the diagnostic process. In this case, the diagnosis of cancer may not 
have been transferred into the hospital records. Because of this possible 
systematic bias in the records, we chose to use a 6-month lag-period in 
every analysis, i.e. cervical cancer diagnosis was impossible until after 6 
months of follow-up. All women with cervical cancer diagnosed within 6 
months of treatment were excluded from the follow-up, or the follow-up 
of all endpoints started 6 months after treatment, depending on the study 
in question.
In Study I, the comparison in cancer incidence was between the cancer 
incidence of the treated women and the cancer incidence of the general 
population in the Helsinki-Uusimaa region. In Studies III and IV, com-
parisons were between the treated women and their matched reference 
cohort. That other CIN treatments among the women in both reference 
groups also existed was a disadvantage with some effect on our results. 
Treated women in the reference group diminish the difference in risk fac-
tors between the groups and therefore are more likely to slightly dilute 
than to exaggerate our results.
As endpoints, cancer and death almost always are recorded in these 
registers, and no source of possible follow-up bias from missing data 
should therefore be expected in Studies I to III. On the other hand, women 
treated for CIN have most likely participated in intensified follow-up, with 
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several extra colposcopies done after the treatment. Diagnosis of both 
cervical cancer and cancers of the vagina, vulva, and anus are therefore 
more likely to appear earlier among these women, affecting our results. In 
Study IV, diagnosis of extra-uterine pregnancy or spontaneous abortion 
might be somewhat susceptible to follow-up bias: Women less conscious 
of their health might not visit a physician for abnormal vaginal bleeding 
and therefore do not appear in these THL registers. This kind of behavior 
may be more common among the women with CIN. On the other hand, 
women treated for CIN in our data have participated in nationwide or 
spontaneous screening, and attended colposcopy. These women thus 
cannot definitely be assumed not to react to vaginal bleeding at a lower 
rate than would healthy women in the reference populations, meaning no 
significant follow-up bias is likely to arise here, either.
The major confounding factor in cancer incidence, mortality, and 
reproductive health is age. In Studies I and II, all models were adjusted 
for age. In Studies III and IV, as the reference population we used women 
matched by age and municipality of residence at the time of CIN treatment. 
If information in the registers was limited, these limitations were similar 
for both cohorts and therefore do not compromise results. On the other 
hand, the treated women in our cohort were mainly of screening age at 
the time of treatment, under 60 (Table 1). We might thus be partially miss-
ing, in both cancer incidence and mortality analyses, those older women 
who, after cessation of screening, develop invasive cervical cancer.
In study of the treatment effects in depth, especially as to cancer inci-
dence, a major disadvantage was that we lacked systematic information 
about possible treatment failures and multiple treatments which would 
have enabled us to differentiate more carefully the cancer risk after differ-
ent grades of CIN and factors behind its progression to cancer. The clas-
sification system in the hospital records prevented us from differentiating 
between laser ablation and laser conization. This would have provided 
us the opportunity to analyze excisional and ablational treatments sepa-
rately.
One of our main goals was to determine cervical cancer mortality 
among the women treated for CIN. Among them, we observed only three 
deaths due to cervical cancer. Based on that small number of deaths, the 
cervical cancer mortality figures between the cohorts lacked statistical 
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power. Perhaps a retrospective cohort study is not optimal for this kind 
of rare event. Nevertheless, no increase in cervical cancer mortality was 
observable, and adjusting for socio-economic status resulted in an HR of 
1.0. In Finland, due to nationwide screening, cervical cancer is nowadays 
a rare disease, and death from cervical cancer is an even less common 
phenomenon.
One major source of the confounding is lack of information about 
smoking and sexual behavior in Studies I, II, and IV. These missing data 
did not cause a marked problem in evaluating the overall effectiveness 
of CIN treatments, but could have left a certain confounding in our com-
parison between the treated and reference populations. Socio-economic 
status correlates with smoking as well as with cervical cancer and CIN 
incidence, and can serve as a surrogate variable for smoking. Still some 
residual confounding can remain in the results. Study III had information 
about socio-economic status, which varied significantly over time, census 
by census; we used socio-economic status from the census nearest to the 
day of treatment. This selection of only one social class to use through-
out the follow-up, even though common in other studies, might not have 
been the most informative to estimate the effect of socio-economic sta-
tus on mortality. Some confounding effect of socio-economic status, and 
therefore of smoking, might remain in our results. On the other hand, ad-
justing for socio-economic status in Study III did not change any results 
significantly. The lack of socio-economic data in other studies can thus be 
considered not a major disadvantage. 
Information about hysterectomies was irretrievable in any of the stud-
ies, or about the exact pregnancy week at spontaneous abortion in Study 
IV. If any bias had occurred due to a larger proportion of hysterectomies 
among CIN patients, it would have diluted, not exaggerated the results of 
cancer incidence, mortality, and pregnancy outcome. Differences in re-
productive outcomes detected in Study IV can therefore be considered 
valid. Use of oral contraceptives, or in Study IV overall willingness to get 
pregnant, might have left some residual confounding in the results. Previ-
ous studies about pre-term births and other adverse pregnancy outcomes 
suggested CIN treatment itself to be the cause of later complications, rather 
than the risk factors predisposing to treatment and to other morbidity. We 
tried to take this into account by estimating the hazard ratio both before 
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and after the treatment; based on the confidence intervals, we were able 
to conclude that the treatment itself seemed not to raise the incidence of 
spontaneous abortions, extra-uterine pregnancies or induced abortions.
10.3 Summary and implications
The risk for cervical cancer after treatment of CIN is elevated for at least 20 
years compared to that of the general population. In addition to cervical 
cancer, women treated for CIN are at increased risk for other HPV-related 
cancers, such as of the vagina, vulva, and anus. Furthermore, risk for lung 
cancer and other smoking-related cancers was also elevated. 
Incidences of cervical cancer and HPV-related gynecological cancers 
are elevated after all the four types of conservative treatments (CKC, cryo-
therapy, laser conization or ablation and LEEP), regardless of the grade 
of CIN treated. CIN 3 or CIN 3+ incidence was significantly elevated af-
ter CKC compared to the colposcopically assisted methods of treatment. 
Even if the effect of treatment is good, the treated women are at increased 
risk for developing cervical cancer compared to the risk in the general 
population, especially at older ages. This calls for intensified surveillance 
and systematic screening likely to last for a lifetime with extra focus on the 
other primary sites as well.
Cervical cancer is a rare disease in Finland, and cervical cancer mor-
tality was not significantly elevated after treatment of CIN. After adjusting 
for socio-economic status, the HR for those treated vs. the reference pop-
ulation was 1.0: The treatment is highly effective: The estimated treatment 
effect of cervical cancer prevention in our data was up to 99%, and only 
three deaths from cervical cancer were observed among the 7 000 women 
treated for the precancerous lesion. Excess mortality among these women 
did, however, occur from other causes, especially from lung and other 
cancers, necessitating even more attention towards cessation of smoking. 
The treatment itself seems neither to elevate the risk for the unwanted 
reproductive health outcomes studied nor to harm fertility. The treated 
women are more fertile and deliver more often than does the reference 
population, also after treatment. The incidence of extra-uterine pregnan-
cies and induced abortions was already elevated before the treatment. 
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General information about the harmlessness of the treatment in regards 
to fertility, measures to reduce anxiety experienced by women about the 
treatment, and especially advisories about the use of contraception, espe-
cially condoms, are important interventions to reduce the rate of induced 
abortions and possibly of ectopic pregnancies, as well as HPV infections.
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11 Conclusions
The following conclusions can be drawn:
 1. We observed that cervical cancer incidence, HPV-related 
  gynecological cancer incidence, and smoking-related cancer 
  incidence were elevated among women treated for CIN.
 2. Neither grade of the CIN lesion nor method of treatment affected 
  the success of CIN treatment in terms of cancer-free survival. 
  In terms of CIN 3 or CIN 3+ free survival, the three colposcopically 
  assisted treatment methods were superior to non-colposcopically 
  assisted CKC. Increasing age at treatment was associated with 
  increasing risk for developing CIN 3 or cervical cancer.
 3. After treatment of any CIN, mortality from cervical cancer was 
  not elevated. Instead, mortality from all HPV-associated cancer, 
  all cancers, and overall mortality were significantly increased 
  compared to levels in the reference population.
 4. Women treated for CIN became pregnant and delivered more often
  than did the reference population. In terms of the pregnancy 
  outcomes studied, the CIN treatment itself did not raise 
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  the incidence of induced abortions or of abnormal pregnancies. 
  The CIN treatment had no negative effect on future fertility.
Altogether, the conservative ablative and excisional treatment meth-
ods for CIN are effective in terms of cervical cancer prevention and are 
safe in terms of the outcomes studied regarding future fertility. As the 
cancer risk subsequent to treatment is elevated for at least 20 years, the 
proper follow-up is as important as the treatment itself to catch the inevi-
table cancer cases sufficiently early to avoid cancer deaths. 
CIN can be considered a risk-marker: It is a marker for increased 
cancer incidence, for increased cancer and overall mortality, and for in-
creased extra uterine pregnancy and induced-abortion incidence. These 
are not caused only by HPV; smoking, genital tract infections, and perhaps 
psychosocial factors also play a major role. In the management process 
for CIN patients, regular condom use and most of all cessation of smoking 
require encouragement.
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